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ABSTRACT: The phospholipase A and acyltransferase (PLAAT) family of cysteine hydrolases consists of five members, which are
involved in the Ca2+-independent production of N-acylphosphatidylethanolamines (NAPEs). NAPEs are lipid precursors for
bioactive N-acylethanolamines (NAEs) that are involved in various physiological processes such as food intake, pain, inflammation,
stress, and anxiety. Recently, we identified α-ketoamides as the first pan-active PLAAT inhibitor scaffold that reduced arachidonic
acid levels in PLAAT3-overexpressing U2OS cells and in HepG2 cells. Here, we report the structure−activity relationships of the α-
ketoamide series using activity-based protein profiling. This led to the identification of LEI-301, a nanomolar potent inhibitor for the
PLAAT family members. LEI-301 reduced the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5.
Collectively, LEI-301 may help to dissect the physiological role of the PLAATs.
■ INTRODUCTION
The subfamily of phospholipase A and acyltransferases
(PLAATs) consists of five members with reported roles in
tumor suppression and phospholipid metabolism.1,2 They
belong to the lecithin retinol acyltransferase (LRAT) protein
family that is part of the NlpC/P60 superfamily of thiol
hydrolases. The LRAT family has a conserved catalytic motif of
six amino acids (NCEHFV) containing a cysteine residue that
acts as the active site nucleophile.3 A C-terminal hydrophobic
tail is shared by PLAAT1−4, serving as a single-pass trans-
membrane anchoring domain.4 The physiological functions of
the PLAAT family members are only partly understood.5
PLAATs are multifunctional enzymes that display varying
degrees of N- and O-acyltransferase or phospholipase A1/2
activity in vitro.5−11 In addition, PLAAT4 (also known as
RARRES3, HRASLS4, TIG3, or RIG1) is involved in protein
deacylation of WNT and H-RAS proteins in breast cancer cells,
thereby controlling cell growth.12 Biological functions have been
described for PLAAT3 (also known as PLA2G16, HRASLS3,
AdPLA, or HREV107), which primarily acts as a phospholipase
A1/2 and regulates lipolysis in adipose tissue.
4,10,13 Notably,
Plaat3 knockout mice were protected against diet-induced
obesity.12 Recently, PLAAT3was reported to be a host factor for
picornaviridae by facilitating the entry of viral RNA into the
cytosol from virus-containing endosomes.14,15 As such,
inhibitors of PLAAT3 hold promise as anti-obesity or anti-
viral agents.
Less is known about the other PLAAT enzymes. Ueda and co-
workers reported that in vitro, PLAAT2 (also known as
HRASLS2) displays the highest N-acyltransferase activity of
all PLAATs, followed at some distance by PLAAT5 (also known
Received: March 30, 2020
Published: August 2, 2020
Articlepubs.acs.org/jmc
© 2020 American Chemical Society
9340
https://dx.doi.org/10.1021/acs.jmedchem.0c00522
J. Med. Chem. 2020, 63, 9340−9359
This is an open access article published under a Creative Commons Non-Commercial No
Derivative Works (CC-BY-NC-ND) Attribution License, which permits copying and






















































































as iNAT or HRASLS5).16 This reaction involves the transfer of
an acyl group from phosphatidylcholine (PC) to phosphatidy-
lethanolamine (PE), generating N-acylphosphatidylethanol-
amine (NAPE) and lyso-PC (LPC) (Scheme 1). First, the
PLAAT enzyme forms an acyl thioester intermediate using its
Cys-His-His catalytic triad, thereby expelling LPC. This is
followed by the nucleophilic attack of the PE-amino group,
producing the NAPE product and liberating the catalytic
cysteine. NAPEs are an underexplored class of triacylated
phospholipids that serve as precursors for N-acylethanolamines
(NAEs), an important family of signaling molecules that
includes the endocannabinoid anandamide [N-arachidonoyle-
thanolamine (AEA)].17 Through activation of the cannabinoid
CB1 receptor, anandamide is involved in physiological processes
such as appetite, pain sensation, memory formation, stress, and
anxiety.18−20 The canonical enzyme responsible for NAPE
biosynthesis in the brain is a Ca2+-dependent N-acyltransferase
(Ca-NAT), recently identified as PLA2G4E.21 NAPEs are in
turn converted to NAEs in one step by NAPE-phospholipase D
(NAPE-PLD) as well as other multistep pathways.5 In contrast,
the PLAAT family members operate via a calcium-independent
mechanism, providing an alternative pathway through which
NAPEs and NAEs are biosynthesized.16 PLAAT2 was reported
to preferably transfer the sn-1 over the sn-2 acyl group of PC,
which suggests that it mostly generates saturated or mono-
unsaturated NAEs.16 Furthermore, HEK293 cells stably over-
expressing PLAAT2 exhibited highly increased NAPE and NAE
levels. Gene expression of PLAAT2 was found in the lung, liver,
kidney, small intestine, colon, testis, and trachea.9,22 NAEs have
well-established signaling roles in the gastrointestinal system.23
For instance, N-oleoylethanolamine (OEA) was found to act as
a satiety factor via activation of peroxisome proliferator-
activated receptor-α (PPAR-α).24 This raises the possibility
that PLAAT2 is involved in NAE biosynthesis in the gut.
Notably, rodents lack the gene that encodes PLAAT2, thereby
hindering the development of genetic models.9
As of yet, no physiological functions are known for PLAAT5.
Of all PLAAT family members, PLAAT5 does not have a
reported tumor-suppressing role.5 High gene expression levels
were found in testes of mice, rats, and humans as well as in
human pancreas.8,25 PLAAT5 activity was mainly localized to
the cytosol fraction, while an inactive form of the enzyme was
found to be membrane associated.8 In vitro, PLAAT5 displayed
higher N-acyltransferase than phospholipase A1/2 activity.
16
Importantly, compared to PLAAT2, PLAAT5 showed no
preference for the sn-1 or sn-2 acyl group of PC, suggesting
that it could be involved in N-arachidonoyl-PE and thus
anandamide biosynthesis.6,8 PLAAT inhibitors would be
valuable pharmacological tools to study the biological role of
PLAAT2 and PLAAT5.
Scheme 1. Biosynthesis of NAPEs and NAEsa
aThe sn-1 acyl group of PC is transferred to the amine of PE by the
acyltransferase activity of PLA2G4E or PLAAT1−5 forming N-acyl-
PE (NAPE) and LPC. NAPE-PLD hydrolyzes the phosphodiester
bond of NAPE to form NAE and phosphatidic acid (PA). R1, R2, and
R3 denote saturated, mono-, or poly-unsaturated fatty acids. * For the
alternative pathways see ref 5.
Figure 1. Evaluating PLAAT activity using competitive ABPP. (A) Structure of broad-spectrum lipase probe MB064. (B) Representative gel and
apparent IC50 curve of a competitive ABPP experiment for PLAAT2. Labeling by MB064 and dose-dependent inhibition by 1 (apparent pIC50 = 6.2±
0.1, dotted lines show 95% confidence interval). Data represent mean values± SEM (n = 3). Coomassie staining was used as a protein loading control.
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Recently, we described the discovery of α-ketoamide LEI-110
as the first pan-active PLAAT inhibitor using a gel-based
competitive activity-based protein profiling (ABPP) assay.26
LEI-110 was able to reduce arachidonic acid levels in PLAAT3-
overexpressing cells and in HepG2 cells. Here, we report the
structure−activity relationship (SAR) of a library of α-
Table 1. SAR Analysis of Keto- and Hydroxy-amides 1−22
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ketoamides on the PLAAT family members. Next to LEI-110,
we also identified LEI-301 as a nanomolar potent PLAAT2
inhibitor with similar potency for other members of the PLAAT
family, which was selective over the proteins of the
endocannabinoid system (ECS). LEI-301 reduced the NAE
levels in PLAAT2- and PLAAT5-overexpressing cells but not in
control cells. These findings show that LEI-301 is a new
pharmacological tool to study the biological role of PLAATs in
cellular systems.
■ RESULTS AND DISCUSSION
Screening for PLAAT Inhibitors Using Competitive
ABPP. A focused in-house library of lipase inhibitors was
screened for PLAAT inhibition using gel-based competitive
ABPP.26 This method uses an activity-based probe (ABP)
containing an electrophilic group that forms a covalent bond
with the catalytic nucleophile of an enzyme.27 ABPs are also
equipped with a reporter group such as a fluorophore or biotin,
which allows visualization of enzymatic activity in a native
biological setting. In a competitive ABPP experiment, potential
inhibitors are pretreated with a cell lysate that contains the
protein of interest, followed by incubation with an ABP. After
resolving the proteins by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and in-gel fluorescence
scanning, the residual enzymatic activity can be determined by
measuring the probe labeling intensity. Previously, MB064,28
which incorporates a β-lactone electrophilic group, was
validated as an effective ABP for the PLAAT enzyme family.26
Table 2. SAR Analysis of α-Ketoamide Analogues 1 and 23−42
aclogP was calculated using Chemdraw 15.
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Here, cytosol fractions of human embryonic kidney HEK293T
cells that overexpressed PLAAT2−5 were treated with potential
inhibitors (10 μM, 30min), followed by incubation withMB064
(250 nM, 20 min) (Figure 1A). The proteins were then resolved
by SDS-PAGE, and the PLAAT activity was quantified by in-gel
fluorescence scanning. A compound that showed residual
protein labeling of ≤50% was considered to be active. For
these active compounds, an IC50 curve was generated using a
dose−response ABPP experiment (Figure 1B). Data for
PLAAT2, PLAAT3, PLAAT4, and PLAAT5 are reported in
Table 1 as pIC50 ± SEM (n = 3). Unfortunately, PLAAT1 could
not be tested because of a lack of protein expression in
HEK293T cells. α-Ketoamides 1 and 2 were identified as
submicromolar hits, showing similar potency for all tested
PLAAT members. An early SAR emerged from the structurally
similar keto- and hydroxy-amides (3−22) present in this
focused screening library. The α-position of the ketone next to
the amide was essential for binding (compare α-ketoamides 1
and 2 with β-ketoamides 5−8). β-Hydroxyamides (3 and 4)
were inactive. Removing the alkyl spacer (11) was also
detrimental for activity. Furthermore, the phenethylamine of 1
was preferred over benzylamine (9) and ethylamine (10). N-
methylation resulted in complete loss of activity (12), which
suggested that the N−H is potentially involved in hydrogen
bond formation or that the methyl group has a steric clash with
the protein. Similarly, secondary amides incorporating either
(hetero)cyclic (13, 15, 16, and 18−21) or acyclic (14, 17, and
22) motifs did not show any activity.
Evaluation of an α-Ketoamide Inhibitor Library
Delivers Nanomolar Hit LEI-301. α-Ketoamide 1 exhibited
the smallest molecular weight (MW = 316) and highest overall
potency for the PLAAT enzymes; therefore, this compound was
resynthesized and its activity was confirmed on all PLAAT
members with a pIC50 ranging from 6.0 to 6.4 (Table 2). It was
envisioned that the electrophilic ketone of 1 could bind with the
PLAAT active site cysteine through a reversible covalent
mechanism forming a hemithioketal adduct, similar to other
reported α-ketoamide inhibitors.26,29 To test this hypothesis,
compound 23 was prepared, in which the ketone was replaced
by an alcohol. This compound showed no activity at 10 μM
(Table 2), which is in line with the hypothesis.
To systematically investigate the SAR and improve the
potency of 1, R1-ketone and R2-phenethyl analogues were
synthesized (compounds 24−56) (Tables 2 and 3). First, the
effect of various substitutions on the R1-group of 1was evaluated
with derivatives 24−36 (Table 2). The removal of chlorine (24)
was detrimental for the activity for PLAAT2−4 but not
PLAAT5. The length of the alkyl chain was studied in analogues
24−27, showing that the propylene derivative 25 was optimal,
which had increased potency for PLAAT2, PLAAT3, and
PLAAT5. The 4-chloro substituent on the phenyl ring seemed to
be optimal based on the inhibitory activity of compounds 29−
Table 3. SAR Analysis of Phenethyl Analogues 25 and 43−56
acLogP was calculated using Chemdraw 15.
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33. Electron-donating groups such as 4-methyl (29) and 4-
methoxy (32) substituents decreased the potency, but a
lipophilic electron-withdrawing group (e.g., 4-trifluoromethyl,
30) was tolerated for PLAAT5. A small (4-fluoro, 31)
substituent lowered the activity, while a large group (4-phenoxy,
33) provided a selectivity window for PLAAT5 over the other
PLAATs of 10- to 30-fold. Furthermore, the substitution of the
4-chloro to the ortho or meta positions did not result in
improved potency (compounds 34 and 35). The 3,4-dichloro
derivative 36, however, presented increased activities for
PLAAT3 and PLAAT5. Taken together, these compound series
point toward the presence of a small lipophilic pocket, restricted
in size, which is occupied by the alkylphenyl group.
Next, β,γ-unsaturated α-ketoamides 37−42 were evaluated to
test whether conformational restriction of the alkyl linker would
lead to a gain in activity (Table 2). Although unsaturation was
tolerated in the alkyl chain, no or little improvement in potency
was observed for these derivatives (compare compounds 1, 24,
32, and 37−39). Also, 4-bromo, 3-bromo, or 3-phenyl
substitutions (40−42) did not provide the desired inhibitory
activity increase. Overall, this suggests that the R1 group is
positioned toward a shallow pocket.
Next, the focus was shifted toward the optimization of the R2-
phenethyl moiety. Analogues 43−56 incorporating substituted
phenethylamines were prepared in combination with the 2-oxo-
5-phenylpentanoyl motif of compound 25, which demonstrated
the highest PLAAT2 activity (Table 3). The compounds
showed a comparable SAR on PLAAT2 and PLAAT4, as
substitutions on the para position were unfavorable for methyl
(43), methoxy (44), and hydroxyl (46). Substitutions on the
meta and ortho positions (48, 49) or 2,4-disubstituted methoxy
(45) or chloro (50) also did not afford an improvement in
potency. Increasing the lipophilicity gave a 2- to 3-fold increase
in activity for 4-bromo analogue 47. Further expansion with a 4-
phenoxy moiety (51) improved the potency both for PLAAT2
and PLAAT4 by 10-fold compared to 25. The introduction of a
4-methyl group in compound 43 enhanced the inhibitory
activity for PLAAT3 and PLAAT5. Other lipophilic groups [4-
bromo (47) and 4-phenoxy (51)] gave even higher activities for
PLAAT5 especially.
The addition of the phenoxy group increased the clogP of 51
with 2 log units to 6.14 (calculated with Chemdraw 15);
therefore, more polar heteroaryl rings were investigated to lower
the lipophilicity (52−56) (Table 3). Compound 55 (LEI-110)
was identified as the most potent inhibitor of PLAAT3 and its
biological characterization has previously been described in
detail.26 With regard to PLAAT2, a decrease in activity was
observed for compounds 52−56 compared to 51. Therefore,
being the most potent inhibitor of PLAAT2, 51 (termed LEI-
301) was selected for further characterization.
In Silico Modeling of α-Ketoamide Inhibitors. To
explain the binding mode of the α-ketoamide inhibitors in
PLAAT2, LEI-301 and 1 were docked in a PLAAT2 crystal
structure (PDB: 4DPZ).4 Residues 39−52 and 105−111 were
absent from this structure; therefore, a homology model was
prepared using the closely related PLAAT3 crystal structure
(PDB: 4DOT)4 from which the shape of the loop for residues
105−111 could be adopted. A second loop comprising residues
39−52 was modeled based on sequence, as it is not present in
both crystal structures. Because our data suggested that the
electrophilic ketone of α-ketoamides could engage with the
active site cysteine through a reversible covalent mechanism,29
LEI-301 and 1 were covalently docked to Cys113 in the enzyme
(Figure 2). Both compounds revealed a hydrogen bonding
network between the oxy-anion and amide carbonyl with His23
and the Trp24 backbone amide N−H, while the backbone
carbonyl of Leu108 formed a H-bond with the amide of the
inhibitors. Introduction of the 4-phenoxy group in LEI-301
suggested that an additional π−π stacking interaction with
Tyr21 would be possible. This offered a potential reason for the
observed activity increase of LEI-301.
Selectivity Profile of LEI-301 for the ECS. The affinity or
activity of LEI-301 for the receptors and metabolic enzymes of
the ECS was determined to assess its selectivity profile. Minimal
affinity (<50%) was observed at 10 μM for the cannabinoid
receptors types 1 and 2 (CB1/CB2) (Table 4). The enzymes
involved in NAE biosynthesis (PLA2G4E, NAPE-PLD) and
degradation (FAAH) were also not inhibited at this concen-
tration (Table 5). The enzymes involved in the metabolism of
the other endocannabinoid 2-arachidonoylglycerol (2-AG),
such as diacylglycerol lipase α and β (DAGLα/β), mono-
acylglycerol lipase (MAGL), and α,β-hydrolase domain
containing 6 (ABHD6) were not inhibited.
Targeted Lipidomics Shows That LEI-301 Reduces
NAEs in PLAAT2-Overexpressing Cells. Having established
that LEI-301 is a potent inhibitor of PLAAT2 and selective over
the other enzymes of the ECS, it was investigated whether LEI-
301 is active in a cellular setting. To this end, NAE levels, which
are downstream metabolites of NAPEs generated by NAPE-
PLD, were measured in living cells. HumanU2OS osteosarcoma
cells were therefore transiently transfected with a pcDNA3.1
plasmid containing the gene for PLAAT2, PLAAT5, or an empty
(mock) vector. Of note, mRNA of NAPE-PLD was detected by
quantitative PCR (qPCR) in this cell line, suggesting that
NAPEs can be converted to NAEs (NAPEPLD: quantification
cycle Cq ± SEM = 27.3 ± 0.05, RPS18 (housekeeping gene): Cq
± SEM = 17.8 ± 0.01, n = 3; the presence of reference gene
mRNA in combination with a Cq≤ 29 for the targeted mRNA is
considered sufficient30). Targeted lipidomics on the lipid
extracts of the transfected cells allowed the quantification of 8
Figure 2.Docking pose of LEI-301 and 1with PLAAT2. Compounds 1
(blue) and LEI-301 (orange) in complex with PLAAT2, covalently
bound to Cys113. Yellow dotted lines represent a hydrogen bond, and
cyan represents π-interactions.
Table 4. Affinity of LEI-301 for Cannabinoid Receptors CB1
and CB2
radioligand displacement at 10 μM LEI-301 (% ± SD; N = 2, n = 2)
hCB1 hCB2
49 ± 8 32 ± 4
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different NAEs and 10 free fatty acids (FFAs) by liquid
chromatography−mass spectrometry (LC−MS). A striking
increase of 9- to 99-fold for all NAE species was observed for
the PLAAT2-overexpressing cells compared to control,
including anandamide (AEA, 54-fold) (Figure 3A, Table 6).
This result confirms previous findings.16 Notably, PLAAT2
overexpression did not elevate most FFA species except for
arachidonic acid (fold change ± SD = 1.81 ± 0.45, P = 0.04),
while levels of γ-linolenic (18:3-ω6) and linoleic acid (18:2-ω6)
were significantly decreased (Figure 3A, Table S1). In PLAAT5-
transfected cells also a significant increase of NAE content was
observed, although smaller in magnitude compared to PLAAT2
(Figure 3B, Table 6). Interestingly, N-docosahexaenoylethanol-
amine (DHEA) levels were unaffected by overexpression of
PLAAT5. Furthermore, FFA levels including arachidonic acid
were not elevated for this enzyme (Figure 3B, Table S1). Next,
the PLAAT2/PLAAT5 or mock-transfected cells were incu-
bated with 10 μM LEI-301 for 4 h. A significant 2-fold reduction
of anandamide was apparent in the PLAAT2 and PLAAT5 cells,
which was absent in the control samples (for PLAAT2: P =
0.006; for PLAAT5: P < 0.0001) (Figure 3C,F). Other
saturated, mono- and poly-unsaturated NAEs also showed
significant reductions upon treatment with LEI-301 in the
PLAAT2 and PLAAT5 overexpressing cells but not in the mock
cells (Figures 3F, S1). LEI-301 did reduce arachidonic acid
levels in PLAAT2-transfected cells; however, this did not meet
significance (P = 0.06) (Figure 3E). In the case of PLAAT5,
DHEA as well as arachidonic acid levels were not affected by
Table 5. Inhibitory Activities of LEI-301 for Metabolic Enzymes of the ECSa
remaining enzyme activity at 10 μM LEI-301 (% ± SD; n = 3)
hNAPE-PLD hPLA2G4E mDAGLα mDAGLβ hMAGL mFAAH mABHD6
92 ± 8 95 ± 5 97 ± 10 83 ± 1 105 ± 19 108 ± 4 92 ± 5
aActivities were obtained from surrogate (hNAPE-PLD) or natural (hMAGL) substrate assays. hPLA2G4E, mDAGLα/β, mFAAH, and mABHD6
were determined by gel-based ABPP.
Figure 3. U2OS cells transfected with PLAAT2 or PLAAT5 exhibit highly increased NAE levels and LEI-301 can inhibit NAE formation. (A,B)
Volcano plots depicting the log2(fold change) vs−log10(P-value) of NAEs (green diamonds) and FFAs (red circles) in (A) PLAAT2- or (B) PLAAT5-
vs mock-transfected U2OS cells. (C−E) Absolute levels of (C) anandamide (AEA), (D) 2-AG and (E) arachidonic acid in mock-, PLAAT2- or
PLAAT5-transfected cells treated with vehicle (DMSO) or LEI-301 (10 μM, 4 h). (F) Normalized NAE levels of mock-, PLAAT2- or PLAAT5-
transfected cells treated with LEI-301 (10 μM, 4 h) represented as effect %. The data were normalized against mock-, PLAAT2- or PLAAT5-
transfected cells treated with vehicle (DMSO). Absolute values are depicted in Figure S1. Data represent mean values ± SD for four biological
replicates. *, P < 0.05, **, P < 0.01, ***, P < 0.001 by one-way ANOVA.
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treatment with LEI-301 (Figure 3E,F). Notably, LEI-301 did
not alter the levels of the other endocannabinoid 2-AG in all
tested conditions (Figure 3D). Previously, α-ketoamides (also
termed 2-oxo-amides) were reported as inhibitors of various
PLA2 enzymes.
29,31−34 To test the selectivity of LEI-301 in
U2OS cells, we performed competitive ABPP experiments in
membrane and cytosol fractions with broad-spectrum lipase
probes fluorophosphonate-carboxytetramethylrhodamine (FP-
TAMRA) and MB064. No inhibitory activity was observed for
LEI-301 at 10 μM for any of the probe-labeled enzymes (Figure
S2A). In addition, members of the PLA2G4 family were also not
inhibited by LEI-301 (Figure S2B,C). Taken together, these
results indicate that LEI-301 can be used to study the biological
roles of PLAAT2 and PLAAT5 in cellular systems.
■ CONCLUSIONS
In summary, we have described the discovery and optimization
of an α-ketoamide inhibitor library for the PLAAT enzyme
subfamily. The SAR of the R1-ketone moiety proved to be
narrow with little room for expansion (Figure 4). The R2-
phenethylamine side did allow the introduction of a large
hydrophobic para-phenoxy group, which led to the identi-
Table 6. PLAAT2 and PLAAT5 Overexpression Greatly Increases the NAE Content in U2OS Cellsa,b
absolute NAE levels (pmol/106 cells ± SD) fold change ± SD P-value
NAE mock PLAAT2 PLAAT5 PLAAT2/mock PLAAT5/mock PLAAT2 PLAAT5
PEA (16:0) 0.196 ± 0.05 18.62 ± 5.97 0.569 ± 0.10 95 ± 30 2.9 ± 0.5 0.0008 0.0005
POEA (16:1) 0.031 ± 0.01 2.247 ± 0.78 0.093 ± 0.01 73 ± 25 3.0 ± 0.4 0.0013 0.0001
SEA (18:0) 0.516 ± 0.12 47.39 ± 13.1 2.916 ± 0.42 92 ± 25 5.7 ± 0.8 0.0004 <0.0001
OEA (18:1) 0.190 ± 0.05 18.83 ± 5.02 1.027 ± 0.17 99 ± 26 5.4 ± 0.9 0.0003 0.0001
LEA (18:2) 0.047 ± 0.01 1.569 ± 0.50 0.121 ± 0.01 33 ± 10 2.6 ± 0.3 0.0009 0.0002
AEA (20:4) 0.040 ± 0.01 2.194 ± 0.79 0.337 ± 0.09 54 ± 20 8.4 ± 2.2 0.0016 0.0005
EPEA (20:5) 0.010 ± 0.01 0.555 ± 0.15 0.059 ± 0.01 53 ± 14 5.7 ± 0.8 0.0004 <0.0001
DHEA (22:6) 0.032 ± 0.01 0.286 ± 0.11 0.027 ± 0.01 8.9 ± 3.4 0.84 ± 0.1 0.0034 0.1886
aData represent mean values ± SD for four biological replicates. P-values were determined by one-way ANOVA. bAbbreviations: PEA = N-
palmitoylethanolamine, POEA = N-palmitoleoylethanolamine, SEA = N-stearoylethanolamine, OEA = N-oleoylethanolamine, LEA = N-
linoleoylethanolamine, AEA = N-arachidonoylethanolamine, EPEA = N-eicosapentaenoylethanolamine, DHEA = N-docosahexaenoylethanolamine.
Figure 4. Structure−activity map for the PLAAT α-ketoamide inhibitor library.
Scheme 2. General Synthetic Routes for (A) α-Ketoamide 1 Analogues, (B) β,γ-Unsaturated α-Ketoamides, and (C) O-
Heteroaryl Phenethylamine Derivativesa
aReagents and conditions: (a) (i) t-BuOH, THF, 0 °C; (ii) N,O-dimethylhydroxylamine·HCl, Et3N, 0 °C, 75%; (b) (i) Mg, alkylbromide, Et2O,
reflux; (ii) Weinreb amide, −78 °C, 21−83%; (c) TFA, DCM, rt, 99%; (d) HATU or HCTU, DiPEA, amine, DMF, rt, 22−80%; (e) NaBH4, THF,
rt, 72%. (f) Pyruvic acid or sodium pyruvate, KOH, MeOH, 0 °C to rt; (g) (i) oxalyl chloride, DCM, 0 °C to rt; (ii) phenethylamine, DCM, 0 °C
to rt, 14−35% over two steps. (h) Boc2O, NaHCO3, THF, H2O, rt, 85%; (i) heteroaryl halide, K2CO3, DMSO or DMF, rt or 85 °C, 63−92%; (j)
HCl, dioxane, rt, 99%; (k) EDC·HCl, HOBt, ketoacid, NMM, DCM, 0 °C to rt, 15−30%.
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fication of LEI-301 as a potent inhibitor for PLAAT2−5, having
a 10-fold higher potency for PLAAT2 and PLAAT5 than our
initial hit. Covalent docking in the PLAAT2 crystal structure
provided a possible binding mode of LEI-301. Overexpression
of PLAAT2 in U2OS cells resulted in a large increase of all
measured NAE species, including the endocannabinoid
anandamide, whereas no significant elevations of FFAs were
observed except for arachidonic acid. Also PLAAT5 was able to
increase the NAE content upon transient transfection, although
this was smaller in magnitude compared to PLAAT2. These
findings support the notion that PLAAT2 and PLAAT5 are
involved in the biosynthetic pathways of the NAEs.
Furthermore, treatment of overexpressing PLAAT2 and
PLAAT5 cells with LEI-301 gave a twofold reduction of
anandamide levels, which was absent in control cells. This
validates LEI-301 as a promising tool compound to study
PLAAT2 and PLAAT5 functions in biological systems. LEI-301
allows acute blockade of these enzymes, which can be beneficial
compared to genetic knockout models, where long-term
compensatory effects can occur. In addition, Plaat2 is not
present in the rodent genome, which hampers the study of its
biological function. Currently, it is unknown if the Ca2+-
independent PLAAT enzymes contribute to physiological
NAPE and thus NAE biosynthesis. In contrast to the Ca2+-
dependent NAPE production by PLA2G4E, PLAATs may
continuously produce NAPEs from their abundant PE and PC
substrates. So far, PLA2G4E activity has been reported in heart,
brain, and skeletal muscles.21 Peripheral organs such as kidney,
small intestine, and testis have well established NAE signaling
roles and reported PLAAT2 or PLAAT5 expression.5,18
Furthermore, these tissues show low Ca2+-dependent
PLA2G4E activity.21 Therefore, these organs are prime
candidates to assess the contribution of PLAAT enzymes with
regard to NAPE and NAE formation using the inhibitors here
disclosed.
■ CHEMISTRY
Oxalyl chloride (57) was reacted with tert-butanol and N,O-
dimethylhydroxylamine·HCl, giving Weinreb amide 58. Treat-
ment with an in situ formed Grignard reagent from 4-
chlorophenethyl bromide followed by tert-butyl deprotection
gave ketoacid 60a. Finally, amide coupling using HCTU
afforded α-ketoamide 1.
R1-derivatives 24−36 and R2-analogues 43−51 were
synthesized via the general route (Scheme 2A). β,γ-Unsaturated
α-ketoamides (37−42) were prepared using a two-step
procedure (Scheme 2B): condensation of benzaldehyde
(61a−f) with pyruvic acid, which afforded the β,γ-unsaturated
α-ketoacid as the potassium salt (62a−f), followed by acid
chloride formation and coupling with phenethylamine. O-
Arylated 4-hydroxyphenethylamine derivatives 52−56 were
synthesized via Scheme 2C. Tyramine (63) was Boc-protected,
followed by nucleophilic aromatic substitution (SNAr) with a
heteroaryl halide. Boc deprotection and subsequent amide
coupling provided the α-ketoamides 52−56.
■ EXPERIMENTAL SECTION
Biological Procedures. Plasmids. Full-length cDNA of human
PLAAT1−5 (obtained from prof. Ueda8) was cloned into mammalian
expression vector pcDNA3.1 with a C-terminal FLAG-tag and
containing genes for ampicillin and neomycin resistance. Plasmids
were isolated from transformed XL10-Gold competent cells (prepared
using Escherichia coli transformation buffer set; Zymo Research) using
plasmid isolation kits following the supplier’s protocol (Qiagen). All
sequences were analyzed by Sanger sequencing (Macrogen) and
verified (CLC Main Workbench).
Cell Culture. HEK293T and U2OS cells (ATCC) were cultured at
37 °C and 7% CO2 in Dulbecco’s modified Eagle’s medium (Sigma-
Aldrich, D6546) with GlutaMax (2 mM), penicillin (100 μg/mL,
Duchefa), streptomycin (100 μg/mL, Duchefa), and 10% (v/v)
newborn calf serum (Seradigm). The medium was refreshed every 2−3
days, and cells were passaged twice a week at 80−90% confluence. The
cells were passaged twice a week by thorough pipetting (HEK293T) or
trypsinization (U2OS) to appropriate confluence.
Transient Transfection. Transient transfection was performed, as
described previously.26 In brief, 107 HEK293T cells were seeded in 15
cm Petri dishes 1 day before transfection. Two hours before
transfection, the medium was refreshed with 13 mL of the medium.
Transfection was performed with polyethyleneimine (PEI, 60 μg per
dish) in a ratio of 3:1 with plasmid DNA (20 μg per dish). PEI and
plasmid DNA were incubated in a serum-free medium (2 mL per dish)
at rt for 15 min, followed by dropwise addition to the cells. Transfection
with the empty pcDNA3.1 vector was used to generate control (mock)
samples. The mediumwas refreshed after 24 h, and cells were harvested
after 48 or 72 h in cold phosphate-buffered saline (PBS). Cells were
pelleted by centrifugation (5 min, 1000g), and the pellet was washed
with PBS. The supernatant was removed and cell pellets were flash-
frozen in liquid N2 and stored at −80 °C.
Cell Lysate Preparation. Cell pellets were thawed on ice,
resuspended in cold lysis buffer [50 mM Tris-HCl pH 8, 2 mM
dithiothreitol (DTT), 1 mM MgCl2, 2.5 U/mL benzonase], and
incubated on ice for 30 min. The cytosolic fraction (supernatant) was
separated from the membranes by ultra-centrifugation (100,000g, 45
min, 4 °C, Beckman Coulter, Ti 70.1 rotor). The pellet (membrane
fraction) was resuspended in cold storage buffer (50 mM Tris-HCl pH
8, 2 mM DTT) and homogenized by thorough pipetting and passage
through an insulin needle (29G). Protein concentrations were
determined by a Quick Start Bradford protein assay (Bio-Rad) or
Qubit protein assay (Invitrogen). The samples were flash-frozen in
liquid N2 and stored at −80 °C.
Mouse Brain Lysate Preparation.Mouse brains were thawed on ice,
dounce homogenized in cold lysis buffer (20mMHEPES pH 7.2, 2 mM
DTT, 1 mMMgCl2, 2.5 U/mL benzonase), and incubated on ice for 30
min. The membrane and cytosolic fractions of cell or tissue lysates were
separated by ultracentrifugation (100,000g, 45 min, 4 °C). The
supernatant was collected (cytosolic fraction) and the membrane pellet
was resuspended in cold storage buffer (20 mMHEPES pH 7.2, 2 mM
DTT) and homogenized by thorough pipetting and passage through an
insulin needle (29G). Protein concentrations were determined using a
Bradford assay (Bio-Rad). The samples were flash-frozen in liquid N2
and stored at −80 °C.
ABPP on PLAAT2−5 Transfected HEK293T Cell Lysate. Gel-based
ABPP was performed with minor changes, as described previously.26
For ABPP assays on HEK293T cells overexpressing PLAAT2, the
cytosol proteome (0.25 μg/μL, 20 μL) was preincubated with a vehicle
(DMSO) or inhibitor (0.5 μL in DMSO, 30 min, rt), followed by
incubation with MB064 (final concentration: 250 nM, 20 min, rt). For
PLAAT3, PLAAT4, and PLAAT5, the protocols differed for the protein
concentrations (0.5, 1, and 1 μg/μL, respectively) and MB064
concentrations (250, 500, and 500 nM, respectively). The final
concentrations for the inhibitors are indicated in the main text and
figure legends. For the dose−response experiments, only cytosol
proteome was used. Proteins were denatured with 4× Laemmli buffer
[5 μL, stock concentration: 240 mM Tris pH 6.8, 8% (w/v) SDS, 40%
(v/v) glycerol, 5% (v/v) β-mercaptoethanol, 0.04% (v/v) bromophe-
nol blue]. Ten μL of sample per reaction was resolved on a 10%
acrylamide SDS-PAGE gel (180 V, 70 min). Gels were scanned using
Cy3 and Cy5 multichannel settings (605/50 and 695/55 filters,
respectively) on a ChemiDoc Imaging System (Bio-Rad). Fluorescence
was normalized to Coomassie staining and quantified with Image Lab
(Bio-Rad). The experiments were performed in triplicate. Dose−
response IC50 curves were generated with GraphPad Prism 6.
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qPCR. For primer sequences used, see Table S2. RNA isolation and
cDNA synthesis: total RNA from U2OS cells was extracted using a
NucleoSpin RNA kit (Macherey-Nagel) according to the manufac-
turer’s instructions. Subsequently, cDNA synthesis was carried out with
a SuperScript First-Strand Synthesis System (Invitrogen) according to
the manufacturer’s instructions. qPCR analysis: 2.5 ng of input cDNA
was analyzed using SYBRGreen qPCR master mix (Thermo Fisher) on
a CFX96 optical thermal cycler (Bio-Rad). Data analysis was performed
using CFX Manager software (Bio-Rad). The housekeeping gene 40S
ribosomal protein S18 (RPS18) was used as a control. The data are
expressed in quantitation cycles (Cq) ± SEM of three technical
replicates.
Radioligand Displacement Assays for CB1 and CB2 Receptors.
[3H]CP55940 displacement assays to determine the affinity for the
cannabinoid CB1 and CB2 receptors were performed, as previously
described.35
NAPE-PLD Surrogate Substrate (PED6) Activity Assay. The human
NAPE-PLD activity assay was performed, as previously described.35
Natural Substrate-Based Fluorescence Assay MAGL. The natural
substrate assay for human MAGL was performed, as reported
previously.36
ABPP for Determining mDAGLα/β, mFAAH, mABHD6, and
hPLA2G4E Activities. Gel-based ABPP was performed, as previously
described.28 In brief, mouse brain membrane proteome or hPLA2G4E-
overexpressing membrane lysate (9.5 μL and 2 μg/μL or 19.5 μL and 1
μg/μL, respectively) was preincubated with a vehicle or inhibitor (0.5
μL 20× or 0.5 μL 40× inhibitor stock in DMSO, respectively, 30 min,
rt), followed by incubation with the activity-based probe MB064 (250
nM, 0.5 μL 20× stock in DMSO) or FP-TAMRA (500 nM, 0.5 μL 20×
stock in DMSO) for mouse brain lysate (15min, rt) or FP-TAMRA (50
nM, 0.5 μL 40× stock in DMSO) for PLA2G4E overexpressing lysate
(5 min, rt). The final concentrations for the inhibitors are indicated in
the main text and figure legends. Proteins were denatured with 4×
Laemmli buffer (3.5 μL, stock concentrations: 240 mM Tris-HCl pH
6.8, 8% w/v SDS, 40% v/v glycerol, 5% v/v β-mercaptoethanol, 0.04%
v/v bromophenol blue, 30 min, rt). The samples (10 μL per slot) were
resolved by SDS-PAGE (respectively, 10 or 8% acrylamide for mouse
brain or PLA2G4E lysate, 180 V, 75 min). Gels were scanned using Cy3
and Cy5 multichannel settings (605/50 and 695/55 filters,
respectively) on a ChemiDoc Imaging System (Bio-Rad). Fluorescence
was normalized to Coomassie staining and quantified with Image Lab
(Bio-Rad).
ABPP for Determining the Selectivity Profile of LEI-301 in U2OS
Cell Lysates.U2OS cytosol or membrane lysate (19 μL, 2.5 μg/μL)was
preincubated with a vehicle or inhibitor (0.5 μL 40× stock in DMSO,
30 min, rt), followed by incubation with the activity-based probe
MB064 (2 μM, 0.5 μL 40× stock in DMSO, 15 min, rt) or FP-TAMRA
(500 nM, 0.5 μL 40× stock in DMSO, 15 min, rt). The final
concentrations for the inhibitors are indicated in the figure legends.
Proteins were denatured with 3× Laemmli buffer (10 μL, stock
concentrations: 240 mM Tris-HCl pH 6.8, 8% w/v SDS, 40% v/v
glycerol, 5% v/v β-mercaptoethanol, 0.04% v/v bromophenol blue, 15
min, rt). The samples (12.5 μL per slot) were resolved by SDS-PAGE
(180 V, 75 min). Gels were scanned using Cy3 and Cy5 multichannel
settings (605/50 and 695/55 filters, respectively) on a ChemiDoc
Imaging System (Bio-Rad). Fluorescence was normalized to
Coomassie staining and quantified with Image Lab (Bio-Rad).
ABPP for Determining PLA2G4B, PLA2G4C, and PLA2G4D
Activities. hPLA2G4B, hPLA2G4C, or hPLA2G4D-overexpressing
membrane lysate (19 μL, 1 μg/μL) was pre-incubated with a vehicle or
inhibitor (0.5 μL 40× inhibitor stock in DMSO, 30min, rt), followed by
incubation with the activity-based probe FP-TAMRA (500 nM, 0.5 μL
20× stock in DMSO, 20 min, rt). The final concentrations for the
inhibitors are indicated in the figure legends. Proteins were denatured
with 3× Laemmli buffer (10 μL, stock concentrations: 240 mM Tris-
HCl pH 6.8, 8%w/v SDS, 40% v/v glycerol, 5% v/v β-mercaptoethanol,
0.04% v/v bromophenol blue, 30 min, rt). The samples (12.5 μL per
slot) were resolved by SDS-PAGE (180 V, 75 min). Gels were scanned
using Cy3 and Cy5 multichannel settings (605/50 and 695/55 filters,
respectively) on a ChemiDoc Imaging System (Bio-Rad). Fluorescence
was normalized to Coomassie staining and quantified with Image Lab
(Bio-Rad).
ABPP for Determining the PLA2G4A Activity. Recombinant full-
length human PLA2G4A (0.73 μL, 440 ng/μL, R&D systems, 6659-
PL) was diluted with assay buffer (13.3 μL, 50 mM Tris HCl pH 8.0,
NaCl 500 mM, CaCl2 20 mM in Milli-Q) and preincubated with a
vehicle or inhibitor (0.5 μL 29× inhibitor stock in DMSO, 30 min, 37
°C). FP-alkyne was used as a positive control.37 This was followed by
incubation with FP-TAMRA (500 nM, 0.5 μL 30× inhibitor stock in
DMSO, 20 min, rt). The final concentrations for the inhibitors are
indicated in the figure legends. Proteins were denatured with 4×
Laemmli buffer (5 μL, stock concentrations: 240 mMTris-HCl pH 6.8,
8% w/v SDS, 40% v/v glycerol, 5% v/v β-mercaptoethanol, 0.04% v/v
bromophenol blue, 30 min, 95 °C). The samples (12.5 μL,∼200 ng per
slot) were resolved by SDS-PAGE (180 V, 75 min). Gels were scanned
using Cy3 and Cy5 multichannel settings (605/50 and 695/55 filters,
respectively) on a ChemiDoc Imaging System (Bio-Rad). Fluorescence
was normalized to Coomassie staining and quantified with Image Lab
(Bio-Rad).
Targeted Lipidomics in U2OS Cells. The targeted lipidomic
experiments are based on previously reported methods with small
alterations as specified below.38
Sample Preparation.U2OS cells (2× 106, grown at 37 °C, 7%CO2)
were seeded 1 day before transfection in 6 cm dishes. After 24 h,
PLAAT2, PLAAT5, or mock plasmid DNA (2.7 μg/dish) and PEI (1
μg/μL, 8 μg/dish) were incubated in a serum-free culture medium (15
min, rt) and then added dropwise to the cells in a ratio of 1:5 (plasmid/
PEI). After 24 h, the medium was aspirated and cells were washed once
with serum-free medium. A new serum-free medium was added with
LEI-301 (final concentration: 10 μM, 0.1% DMSO) or DMSO as a
control. After incubating for 4 h (37 °C, 7% CO2), the medium was
removed and the cells were washed with cold PBS (3×). The cells were
harvested in 1.5 mL Eppendorf tubes by trypsinization, followed by
centrifugation (10 min, 1500 rpm). PBS was removed, and the cell
pellets were flash-frozen with liquid N2 and stored at −80 °C. Live cell
count with trypan blue was performed after compound treatment to test
for cell viability and for sample normalization after lipid measurements.
Lipid Extraction. Lipid extraction was performed on ice. In brief, cell
pellets with 2 × 106 cells were spiked with 10 μL each of deuterium-
labeled internal standard mix for endocannabinoids [AEA-d8, DHEA-
d4, 2-AG-d8, N-stearoylethanolamine (SEA)-d3, N-palmitoylethanol-
amine (PEA)-d4, N-linoleoylethanolamine (LEA)-d3, and N-oleoyle-
thanolamine (OEA)-d4] and negative polar lipids (FA 17:0-d33),
followed by the addition of ammonium acetate buffer (100 μL, 0.1 M,
pH 4). After extraction with methyl tert-butyl ether (MTBE, 1 mL), the
tubes were thoroughlymixed for 4min using a bullet blender at medium
speed (Next Advance Inc., Averill park, NY, USA), followed by a
centrifugation step (5000g, 12 min, 4 °C). Then, 925 μL of the upper
MTBE layer was transferred into clean 1.5 mL Eppendorf tubes. The
samples were dried in a SpeedVac, followed by reconstitution in
acetonitrile/water (50 μL, 90:10, v/v). The samples were centrifuged
(14,000g, 3 min, 4 °C) before transferring into LC−MS vials. Each
sample was injected on two different lipidomic platforms: endocanna-
binoids (5 μL) and negative polar lipids (8 μL).
LC−MS/MS Analysis for Endocannabinoids. A targeted analysis of
endocannabinoids and related NAEs was measured using an Acquity
UPLC I class binary solvent manager pump (Waters, Milford, USA) in
conjugation with AB SCIEX 6500 quadrupole ion trap (QTRAP) (AB
Sciex, Massachusetts, USA). Separation was performed with an Acquity
HSS T3 column (1.2 × 100 mm, 1.8 μm) maintained at 40 °C. The
aqueous mobile phase A consisted of 2 mM ammonium formate and 10
mM formic acid, and the organic mobile phase B was acetonitrile. The
flow rate was set to 0.4 mL/min; the initial gradient conditions were
55% B held for 2 min and linearly ramped to 100% B over 6 min and
held for 2 min; after 10 s, the system returned to initial conditions and
held for 2 min before next injection. Electrospray ionization-MS was
operated in positive mode for measurement of endocannabinoids and
NAEs, and a selective multiple reaction mode was used for
quantification.
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LC−MS/MS Analysis for Negative Polar Lipids. This method is
measured on an Acquity UPLC binary solvent manager 8 pump
(Waters) coupled to an Agilent 6530 electrospray ionization quadru-
pole time-of-flight (ESI-Q-TOF, Agilent, Jose, CA, USA) high-
resolution mass spectrometer using reference mass correction. The
chromatographic separation was achieved on an Acquity HSS T3
column (1.2 × 100 mm, 1.8 μm) maintained at 40 °C. The negative
apolar lipids that constitute FFAs were separated with a flow of 0.4 mL/
min over a 15 min gradient. In negative mode, the aqueous mobile
phase A consisted of 5:95 (v/v) acetonitrile/H2O with 10 mM
ammonium formate, and the organic mobile phase B consisted of 99%
(v/v) methanol with 10 mM ammonium formate.
Statistical Analysis. Absolute values of lipid levels were corrected
using the measured live cell count numbers (cell viability was >90%).
The data were tested for significance with GraphPad v6 using one-way
ANOVA with Tukey correction for multiple comparisons. P-values <
0.05 were considered significant.
Computational Chemistry. Ligand Preparation. Molecular
structures of LEI-301 and 1 were drawn with specified chirality and
prepared for docking using Ligprep from Schrödinger.39 Default
Ligprep settings were applied: states of heteroatoms were generated
using Epik at a pH 7.40 No tautomers were created by the program,
which resulted in one standardized structure per ligand.
Protein Preparation. The X-ray structure of PLAAT2 was extracted
from the PDB (PDB ID: 4DPZ).4 The apo protein structure was
prepared for docking with the Protein Preparation tool from the
Schrödinger 2017-4 suite.Waters were removed, and explicit hydrogens
were added. Missing side chains and loops were added with homology
modeling using Prime:41 loops 39−53 were modeled based on the
protein sequence and loops 105−111 were based on the structure of
PLAAT3 (PDB ID: 4DOT).4
Docking. The PLAAT2 binding pocket was induced using the
binding pose from 1 in PLAAT3, as previously reported.26,42 The
complex of superposed 1 covalently bound to PLAAT2 was optimized
using molecular dynamic simulations (10 ns). Compound 1 was
removed, and the cysteine was restored to its nonbonded state.
Subsequently, LEI-301 and 1 were covalently docked to Cys113 using
the Schrödinger 2017-4 suite.42 The poses with the lowest docking
scores were manually examined, and one pose per ligand was selected.
Selection was based on the docking score, frequency of recurring poses,
and interactions made between the ligand and the protein.
Synthetic Procedures. General. All chemicals (Sigma-Aldrich,
Fluka, Acros, Merck) were used as received. All solvents used for
reactions were of analytical grade. Tetrahydrofuran (THF), Et2O,
dimethylformamide (DMF), CH3CN, and dichloromethane (DCM)
were dried over activated 4 Å molecular sieves, and MeOH was dried
over 3 Å molecular sieves. Flash chromatography was performed on
silica gel (Screening Devices BV, 40−63 μm, 60 Å). The eluent EtOAc
was of technical grade and distilled before use. Reactions were
monitored by thin-layer chromatography (TLC) analysis using Merck
aluminium sheets (Silica gel 60, F254). Compounds were visualized by
UV absorption (254 nm) and spraying for general compounds KMnO4
(20 g/L) and K2CO3 (10 g/L) in water or for amines ninhydrin (0.75
g/L) and acetic acid (12.5 mL/L) in ethanol, followed by charring at
∼150 °C. 1H and 13C NMR experiments were recorded on a Bruker
AV-300 (300/75 MHz), Bruker AV-400 (400/100 MHz), or Bruker
DMX-400 (400/101 MHz). Chemical shifts are given in ppm (δ)
relative to tetramethylsilane or CDCl3 as internal standards. Multi-
plicity: s = singlet, br s = broad singlet, d = doublet, dd = doublet of
doublet, t = triplet, q = quartet, p = pentet, m = multiplet. Coupling
constants (J) are given in Hz. LC−MS measurements were performed
on a Thermo Finnigan LCQ Advantage MAX ion-trap mass
spectrometer (ESI+) coupled to a Surveyor HPLC system (Thermo
Finnigan) equipped with a standard C18 (Gemini, 4.6 mmD × 50
mmL, 5 μm particle size, Phenomenex) analytical column and buffers
A: H2O, B: CH3CN, C: 0.1% aq trifluoroacetic acid (TFA). High-
resolution mass spectra were recorded on a LTQ Orbitrap (Thermo
Finnigan) mass spectrometer or a Synapt G2-Si high definition mass
spectrometer (Waters) equipped with an electrospray ion source in
positive mode (source voltage 3.5 kV, sheath gas flow 10 mL/min,
capillary temperature 250 °C) with resolution R = 60,000 at m/z 400
(mass range m/z = 150−2000) and dioctylphthalate (m/z =
391.28428) as a lock mass. Preparative high-performance liquid
chromatography (HPLC) was performed on a Waters Acquity Ultra
Performance LC with a C18 column (Gemini, 150 × 21.2 mm,
Phenomenex). All final compounds were determined to be >95% pure
by integrating UV intensity recorded via HPLC.
General Procedure A: α-Ketoester Synthesis. Magnesium turnings
were activated by stirring in a 3 M solution of HCl for 5 min. The
magnesium was then washed with water and acetone and dried under
reduced pressure. A round-bottom flask connected to a reflux
condenser was flame-dried before the addition of activated magnesium
turnings (2 equiv) under an argon atmosphere. Dry Et2O (2 mL) and a
small piece of iodine were added followed by dropwise addition of a
solution of alkyl bromide (1−1.5 equiv) in dry Et2O (1 M). The
reaction was initiated with a heat gun and refluxed for 1 h. In a separate
flask, a solution of the Weinreb amide 58 (1 equiv) in dry Et2O (1 M)
was prepared and cooled to −78 °C. The Grignard solution was taken
up by syringe and added dropwise to theWeinreb amide solution. After
stirring for 2 h at−78 °C, the reaction was quenched with sat. aqNH4Cl
and extracted with Et2O (2×). The combined organic layers were dried
(MgSO4), filtered, and concentrated under reduced pressure. The
crude residue was purified using silica gel column chromatography
(EtOAc/pentane), affording the α-ketoester.
General Procedure B: α-Ketoester Deprotection. A round-bottom
flask was charged with α-ketoester (1 equiv), DCM (0.3 M) and TFA
(5−10 equiv) and stirred for 1−24 h at rt. The reaction mixture was
concentrated under reduced pressure after TLC analysis showed
complete consumption of the starting material, followed by
coevaporation with toluene (3×). The obtained α-ketoacid was used
in the next step without further purification.
General Procedure C: α-Ketoamide Synthesis. A round-bottom
flask was charged with α-ketoacid (1 equiv) and DMF (0.2 M). HATU
or HCTU (1−1.2 equiv), N,N-diisopropylethylamine (DiPEA) (1−2
equiv) or Et3N (1−2 equiv), and amine (1−1.1 equiv) were added, and
the mixture was stirred for 2−24 h at rt. Water was added, and the
mixture was extracted with DCM (2×). The combined organic layers
were washed with 1 M HCl, sat. aq NaHCO3, and brine, dried
(MgSO4), filtered, and concentrated under reduced pressure. The
crude residue was purified by silica gel column chromatography
(EtOAc/pentane), affording the α-ketoamide.
General Procedure D: α-Ketoamide Synthesis. A round-bottom
flask was charged with α-ketoacid (1 equiv) and THF or DCM (0.2 M)
at 0 °C. N-(3-(Dimethylamino)propyl)-N′-ethylcarbodiimide (EDC)·
HCl (1−1.5 equiv) and HOBt (1−1.5 equiv) were added, and the
mixture was stirred for 30 min, followed by the addition of NMM
(optional, 4 equiv) and the amine (1.2 equiv). The mixture was stirred
for 1−4 days warming to rt. Work-up involved the addition of sat. aq
NaHCO3 and extraction with EtOAc (2 × 25 mL). The combined
organic layers were washed with brine (1×), dried (MgSO4), filtered,
and concentrated under reduced pressure. The crude residue was
purified by silica gel column chromatography (EtOAc/pentane) or
preparative HPLC, affording the α-ketoamide.
General Procedure E: N-Boc-tyramine O-Arylation via SNAr. A
microwave vial was charged with N-Boc-tyramine 64 (1 equiv),
heteroaryl halide (1 equiv), and K2CO3 (2 equiv) in DMSO or DMF
(0.2−1M) and capped. Themixture was stirred for 24−42 h at 85 °C in
an oil bath until TLC showed complete conversion. The mixture was
diluted with H2O and extracted with EtOAc (3×). The combined
organic layers were washed with brine (1×), dried (MgSO4), filtered,
and concentrated under reduced pressure. The crude residue was
purified by silica gel column chromatography (EtOAc/pentane),
affording the product.
General Procedure F: β,γ-Unsaturated α-Ketoamide Synthesis. A
round-bottom flask was charged with pyruvic acid or sodium pyruvate
(1 equiv), aldehyde (1 equiv), andMeOH (1M) and cooled to 0 °C. A
solution of KOH (2M, 1.5 equiv) in MeOH was added dropwise while
keeping the temperature below 25 °C. The reaction was stirred at rt
overnight, forming a yellow precipitate. The reaction mixture was
filtered, and the precipitate was washed with cold MeOH (2×), Et2O
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(2×) and dried, affording the α-ketoacid as the potassium salt. A new
round-bottom flask was charged with the potassium salt and DCM (0.5
M), and the suspension was sonicated for 20 min. This was followed by
cooling to 0 °C and addition of oxalyl chloride (2 equiv). After
consumption of the potassium salt, the reaction mixture was
concentrated under reduced pressure and coevaporated with toluene
(2×). The α-ketoacid chloride was then dissolved in DCM (0.5M) and
cooled to 0 °C, followed by the addition of phenethylamine (1 equiv)
and Et3N (2 equiv). The reaction was stirred for 2 h. Work-up involved
the addition of H2O and extraction with EtOAc. The organic layer was
then washed with 1 M HCl (2×), sat. aq NaHCO3 (2×), and brine
(1×), dried (MgSO4), filtered, and concentrated under reduced
pressure. The crude residue was purified by silica gel column
chromatography (EtOAc/pentane), affording the α-ketoamide.
4-(4-Chlorophenyl)-2-oxo-N-phenethylbutanamide (1). t-Butyl
deprotection 59a: the α-ketoacid was prepared according to the
general procedure B using α-ketoester 59a (0.85 g, 3.2 mmol, 1 equiv)
and TFA (2.5 mL, 32 mmol, 10 equiv), affording the α-ketoacid 60a
(0.68 g, 3.2 mmol, quant.). Amide coupling: the title compound was
prepared according to the general procedure C using the α-ketoacid 60a
(0.68 g, 3.2 mmol, 1 equiv), phenethylamine(0.15 mL, 1.2 mmol, 1.1
equiv), HATU (1.2 g, 3.2 mmol, 1 equiv), and DiPEA (0.61 mL, 3.5
mmol, 1.1 equiv) in DMF, affording the product (0.70 g, 2.2 mmol,
70%). 1H NMR (300 MHz, CDCl3): δ 7.54−6.79 (m, 10H), 3.52 (q, J
= 6.9 Hz, 2H), 3.21 (t, J = 7.4 Hz, 2H), 2.91−2.73 (m, 4H). 13C NMR
(75 MHz, CDCl3): δ 197.80, 159.82, 138.78, 138.13, 131.88, 129.71,
128.67, 128.60, 128.51, 126.67, 40.44, 38.06, 35.28, 28.35. HRMS:
[C18H18NClO2 + H]
+, 316.1099 calcd, 316.1099 found.
4-(4-Chlorophenyl)-2-hydroxy-N-phenethylbutanamide (23). A
round-bottom flask was charged with α-ketoamide 1 (70 mg, 0.22
mmol, 1 equiv) and THF (1 mL). NaBH4 (12 mg, 0.33 mmol, 1.5
equiv) was added, and the mixture was stirred for 15 min. The reaction
was quenched with water (10 mL) and extracted with EtOAc (1 × 10
mL). The organic layer was washed with 1 M aq HCl (2 × 10 mL) and
brine (1 × 10 mL), dried (MgSO4), filtered, and concentrated under
reduced pressure. Purification by silica gel column chromatography
afforded the product (50 mg, 0.16 mmol, 72%). 1H NMR (400 MHz,
CDCl3): δ 7.34−7.25 (m, 2H), 7.25−7.14 (m, 5H), 7.08 (d, J = 8.4 Hz,
2H), 6.61 (t, J = 5.4 Hz, 1H), 4.03 (dd, J = 7.9, 3.7 Hz, 1H), 3.66−3.40
(m, 2H), 3.24 (br s, 1H), 2.80 (t, J = 7.0 Hz, 2H), 2.65 (t, J = 7.9 Hz,
2H), 2.11−1.97 (m, 1H), 1.90−1.80 (m, 1H). 13C NMR (101 MHz,
CDCl3): δ 173.79, 139.74, 138.63, 131.87, 129.93, 128.81, 128.78,
128.65, 126.74, 71.33, 40.33, 36.38, 35.76, 30.57. HRMS:
[C18H20NClO2 + H]
+, 318.1255 calcd, 318.1252 found.
2-Oxo-N-phenethyl-4-phenylbutanamide (24). t-Butyl deprotec-
tion 59b: the α-ketoacid was prepared according to the general
procedure B using α-ketoester 59b (0.50 g, 2.1 mmol, 1 equiv) andTFA
(0.80 mL, 32 mmol, 5 equiv), affording the α-ketoacid 60b (0.40 g, 2.1
mmol, quant.). Amide coupling: the title compound was prepared
according to the general procedure C using the α-ketoacid 60b (0.20 g,
1.2 mmol, 1 equiv), phenethylamine (0.15 mL, 1.2 mmol, 1.1 equiv),
HCTU (0.48 g, 1.15 mmol, 1 equiv), and DiPEA (0.22 mL, 1.3 mmol,
1.1 equiv) in DMF, affording the product (80 mg, 0.28 mmol, 24%). 1H
NMR (300MHz, CDCl3): δ 7.40−7.07 (m, 10H), 7.07−6.88 (m, 1H),
3.55 (q, J = 6.9 Hz, 2H), 3.26 (t, J = 7.5 Hz, 2H), 2.92 (t, J = 7.5 Hz,
2H), 2.83 (t, J = 7.1 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 198.25,
160.05, 140.46, 138.27, 128.85, 128.77, 128.60, 128.46, 126.85, 126.36,
40.58, 38.40, 35.51, 29.22. HRMS: [C18H19NO2 +H]
+, 282.1489 calcd,
282.1487 found.
2-Oxo-N-phenethyl-5-phenylpentanamide (25). The title com-
pound was prepared according to the general procedure C using the α-
ketoacid 60c (0.12 g, 0.63 mmol, 1 equiv), phenethylamine (86 μL,
0.69mmol, 1.1 equiv), HCTU (0.26 g, 0.63mmol, 1 equiv), andDiPEA
(0.12 mL, 0.70 mmol, 1.1 equiv) in DCM, affording the product (70
mg, 0.24 mmol, 38%). 1H NMR (400 MHz, CDCl3): δ 7.34−7.20 (m,
5H), 7.20−7.13 (m, 5H), 6.98 (br s, 1H), 3.53 (q, J = 7.0 Hz, 2H), 2.92
(t, J = 7.3Hz, 2H), 2.83 (t, J = 7.1Hz, 2H), 2.64 (t, J = 7.6Hz, 2H), 1.92
(p, J = 7.4 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 198.97, 160.15,
141.42, 138.30, 128.83, 128.75, 128.57, 128.51, 126.83, 126.12, 40.56,
36.20, 35.52, 35.12, 24.92. HRMS: [C19H21NO2 +H]
+, 296.1645 calcd,
296.1646 found.
2-Oxo-N-phenethyl-6-phenylhexanamide (26). t-Butyl deprotec-
tion 59d: the α-ketoacid was prepared according to the general
procedure B using α-ketoester 59d (0.33 g, 1.3mmol, 1 equiv) andTFA
(1.9 mL, 25 mmol, 19 equiv), affording the α-ketoacid 60d (0.26 g, 1.3
mmol, quant.). Amide coupling: the title compound was prepared
according to the general procedure C using the α-ketoacid 60d (0.26 g,
1.3 mmol, 1 equiv), phenethylamine (0.22 mL, 1.72 mmol, 1.3 equiv),
HATU (0.59 g, 1.56 mmol, 1.2 equiv), and DiPEA (0.30 mL, 1.72
mmol, 1.3 equiv), affording the product (0.34 g, 1.11 mmol, 71%). 1H
NMR (300MHz, CDCl3): δ 7.43−7.08 (m, 10H), 7.09−6.89 (m, 1H),
3.52 (q, J = 6.9 Hz, 2H), 3.01−2.86 (m, 2H), 2.81 (t, J = 7.1 Hz, 2H),
2.61 (t, J = 7.0 Hz, 2H), 1.62 (p, J = 3.5 Hz, 4H). 13C NMR (75 MHz,
CDCl3): δ 198.99, 160.11, 142.05, 138.25, 128.74, 128.68, 128.40,
128.34, 126.73, 125.81, 40.50, 36.55, 35.62, 35.42, 30.79, 22.81.
HRMS: [C20H23NO2 + H]
+, 310.1802 calcd, 310.1801 found.
2-Oxo-N-phenethyl-2-phenylacetamide (27). t-Butyl deprotection
59e: the α-ketoacid was prepared according to the general procedure B
using α-ketoester 59e (0.68 g, 3.3 mmol, 1 equiv) and TFA (2.4 mL, 32
mmol, 10 equiv), affording the α-ketoacid 60e (0.58 g, 3.2 mmol,
quant.). Amide coupling: the title compound was prepared according to
the general procedure C using the α-ketoacid 60e (0.25 g, 1.7 mmol, 1
equiv), phenethylamine (0.23 mL, 1.8 mmol, 1.1 equiv), HCTU (0.69
g, 1.7 mmol, 1 equiv), and DiPEA (0.32 mL, 1.8 mmol, 1.1 equiv) in
DCM, affording the product (0.22 g, 0.86 mmol, 52%). 1H NMR (400
MHz, CDCl3): δ 8.33−8.19 (m, 2H), 7.62−7.52 (m, 1H), 7.47−7.38
(m, 2H), 7.34−7.26 (m, 2H), 7.26−7.14 (m, 4H), 3.62 (q, J = 7.0 Hz,
2H), 2.88 (t, J = 7.2 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 187.86,
161.98, 138.36, 134.36, 133.30, 131.11, 128.75, 128.72, 128.47, 126.68,
40.60, 35.46. HRMS: [C16H15NO2 + H]
+, 254.1176 calcd, 254.1175
found.
2-Oxo-N-phenethylpropanamide (28). A round-bottom flask was
charged with pyruvic acid (0.79 mL, 12 mmol, 1 equiv) and cooled to 0
°C. Thionyl chloride (0.93 mL, 13 mmol, 1.1 equiv) was added, and the
mixture was stirred for 3 h at rt. The reaction mixture was concentrated
under reduced pressure and coevaporated with toluene (3×). The acid
chloride was dissolved in DCM (50 mL) and cooled to 0 °C.
Phenethylamine (1.5 mL, 12 mmol, 1 equiv) and Et3N (1.8 mL, 13
mmol, 1.1 equiv) were added, and the reaction was stirred for 2 h.
Work-up involved the addition of H2O and extraction with EtOAc. The
organic layer was then washed with 1 M HCl (2×), sat. aq NaHCO3
(2×), and brine (1×), dried (MgSO4), filtered, and concentrated under
reduced pressure. The crude residue was purified by silica gel column
chromatography (EtOAc/pentane), affording the product (100 mg,
0.52 mmol, 4%). 1H NMR (300 MHz, CDCl3): δ 7.43−7.15 (m, 5H),
7.13−6.82 (m, 1H), 3.57 (q, J = 7.0 Hz, 2H), 2.87 (t, J = 7.1 Hz, 2H),
2.47 (s, 3H). 13C NMR (101 MHz, CDCl3): δ 197.16, 160.18, 138.27,
128.88, 128.78, 126.87, 40.65, 35.54, 24.58. HRMS: [C11H13NO2 +
H]+, 192.1019 calcd, 192.1019 found.
2-Oxo-N-phenethyl-4-(p-tolyl)butanamide (29). t-Butyl deprotec-
tion 59f: the α-ketoacid was prepared according to the general
procedure B using α-ketoester 59f (0.54 g, 2.2 mmol, 1 equiv) and TFA
(1.6 mL, 22 mmol, 10 equiv), affording the α-ketoacid 60f (0.42 g, 2.2
mmol, quant.). Amide coupling: the title compound was prepared
according to the general procedure C using the α-ketoacid 60f (0.42 g,
2.2 mmol, 1 equiv), phenethylamine (0.30 mL, 2.4 mmol, 1.1 equiv),
HATU (0.83 g, 2.2mmol, 1 equiv), andDiPEA (0.42mL, 2.4mmol, 1.1
equiv) in DCM, affording the product (0.48 g, 1.6 mmol, 74%). 1H
NMR (300 MHz, CDCl3): δ 7.32−7.23 (m, 2H), 7.23−7.18 (m, 1H),
7.18−7.11 (m, 2H), 7.11−6.97 (m, 5H), 3.51 (q, J = 6.9 Hz, 2H), 3.21
(t, J = 7.5 Hz, 2H), 2.97−2.69 (m, 4H), 2.28 (s, 3H). 13C NMR (75
MHz, CDCl3): δ 198.18, 159.96, 138.21, 137.24, 135.61, 129.12,
128.66, 128.62, 128.18, 126.64, 40.44, 38.37, 35.33, 28.64, 20.97.
HRMS: [C19H21NO2 + H]
+, 296.1645 calcd, 296.1643 found.
2-Oxo-N-phenethyl-4-(4-(trifluoromethyl)phenyl)butanamide
(30). t-Butyl deprotection 59g: the α-ketoacid was prepared according
to the general procedure B using α-ketoester 59g (0.25 g, 0.83 mmol, 1
equiv) and TFA (0.62 mL, 8.3 mmol, 10 equiv), affording the α-
ketoacid 60g (0.20 g, 0.83 mmol, quant.). Amide coupling: The title
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compound was prepared according to the general procedure C using
the α-ketoacid 60g (0.20 g, 0.80 mmol, 1 equiv), phenethylamine (0.11
mL, 0.88 mmol, 1.1 equiv), HATU (0.38 g, 0.80 mmol, 1 equiv), and
DiPEA (0.15 mL, 0.80 mmol, 1.1 equiv) in DMF. Column
chromatography (20 → 60% EtOAc in pentane) afforded the product
(0.22 g, 0.64 mmol, 80%). 1H NMR (400 MHz, CDCl3): δ 7.57 (d, J =
8.1 Hz, 2H), 7.39−7.31 (m, 4H), 7.31−7.25 (m, 1H), 7.25−7.19 (m,
2H), 7.12−7.00 (m, 1H), 3.60 (q, J = 7.0 Hz, 2H), 3.32 (t, J = 7.4 Hz,
2H), 3.01 (t, J = 7.4 Hz, 2H), 2.88 (t, J = 7.1 Hz, 2H). 13C NMR (101
MHz, CDCl3): δ 197.70, 159.88, 144.56 (q, J = 1.3 Hz), 138.19, 128.78,
128.70, 128.48, 126.80, 125.46 (q, J = 3.8 Hz), 124.31 (q, J = 271.8Hz),




deprotection 59h: the α-ketoacid was prepared according to the general
procedure B using α-ketoester 59h (0.15 g, 0.59 mmol, 1 equiv) and
TFA (0.44mL, 5.9 mmol, 10 equiv), affording the α-ketoacid 60h (0.12
g, 0.59 mmol, quant.). Amide coupling: the title compound was
prepared according to the general procedure C using the α-ketoacid
60h (0.12 g, 0.63mmol, 1 equiv), phenethylamine (80 μL, 0.63mmol, 1
equiv), HCTU (0.26 g, 0.63mmol, 1 equiv), and DiPEA (0.12mL, 0.69
mmol, 1.1 equiv) in DMF, affording the product (0.12 g, 0.39 mmol,
62%). 1H NMR (300 MHz, CDCl3): δ 7.35−7.21 (m, 3H), 7.21−7.08
(m, 4H), 7.08−6.99 (m, 1H), 6.99−6.88 (m, 2H), 3.54 (q, J = 6.9 Hz,
2H), 3.22 (t, J = 7.4 Hz, 2H), 2.99−2.64 (m, 4H). 13C NMR (75 MHz,
CDCl3): δ 198.05, 163.13, 159.97, 138.22, 136.05 (d, J = 3.2 Hz),
129.85 (d, J = 7.9 Hz), 128.77 (d, J = 6.8 Hz), 126.82, 115.32 (d, J =
21.2 Hz), 40.55, 38.44, 35.44, 28.39. HRMS: [C18H18FNO2 + H]
+,
300.1394 calcd, 300.1393 found.
4-(4-Methoxyphenyl)-2-oxo-N-phenethylbutanamide (32). A
round-bottom flask was charged with unsaturated α-ketoamide 39
(0.10 g, 0.32 mmol, 1 equiv) and MeOH (1 mL) and flushed with N2.
Pd/C (10 wt %, 10 mg, 9.4 μmol, 3 mol %) was added, and the flask was
purged again with N2, followed by H2, and the reaction was stirred
overnight under a H2 atmosphere (balloon). The reaction was filtered
over celite, which was washed with MeOH, and the filtrate was
concentrated under reduced pressure. The crude residue was purified
by silica gel column chromatography (EtOAc/pentane), affording the
product (50 mg, 0.16 mmol, 50%). 1H NMR (400 MHz, CDCl3): δ
7.36−7.27 (m, 2H), 7.27−7.21 (m, 1H), 7.18 (d, J = 7.0 Hz, 2H), 7.11
(d, J = 8.6 Hz, 2H), 7.05−6.90 (m, 1H), 6.88−6.71 (m, 2H), 3.77 (s,
3H), 3.55 (q, J = 7.0 Hz, 2H), 3.22 (t, J = 7.5 Hz, 2H), 2.95−2.73 (m,
4H). 13C NMR (101 MHz, CDCl3): δ 198.37, 160.05, 158.13, 138.26,
132.48, 129.41, 128.86, 128.77, 126.85, 113.99, 55.35, 40.57, 38.67,
35.51, 28.38. HRMS: [C19H21NO3 + H]
+, 312.1594 calcd, 312.1593
found.
2-Oxo-N-phenethyl-4-(4-phenoxyphenyl)butanamide (33). A
round-bottom flask was charged with unsaturated α-ketoamide 67
(0.12 g, 0.33 mmol, 1 equiv) and MeOH (1 mL) and flushed with N2.
Pd/C (10 wt %, 10 mg, 9.4 μmol, 3 mol %) was added, and the flask was
purged again with N2, followed by H2, and the reaction was stirred
overnight under a H2 atmosphere (balloon). The reaction was filtered
over celite, which was washed with MeOH, and the filtrate was
concentrated under reduced pressure. The ketone was over-reduced to
the alcohol according to NMR analysis; therefore, it was reoxidized. A
round-bottom flask was charged with the alcohol, Dess−Martin
periodinane (0.21 g, 0.49 mmol, 1.5 equiv), and DCM (5 mL) and
stirred at rt. Work-up involved the addition of H2O and extraction with
EtOAc. The organic layer was washed with 1 M HCl (2×), sat. aq
NaHCO3 (2×), and brine (1×), dried (MgSO4), filtered, and
concentrated under reduced pressure. The crude residue was purified
by silica gel column chromatography (EtOAc/pentane), affording the
product (80 mg, 0.23 mmol, 65%). 1H NMR (400 MHz, CDCl3): δ
7.36−7.27 (m, 4H), 7.27−7.20 (m, 1H), 7.20−7.11 (m, 4H), 7.11−
7.04 (m, 1H), 7.04−6.95 (m, 3H), 6.95−6.88 (m, 2H), 3.55 (q, J = 7.0
Hz, 2H), 3.25 (t, J = 7.5Hz, 2H), 2.90 (t, J = 7.5Hz, 2H), 2.84 (t, J = 7.1
Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 198.20, 160.01, 157.51,
155.62, 138.23, 135.36, 129.79, 129.71, 128.85, 128.76, 126.85, 123.16,
119.14, 118.74, 40.58, 38.55, 35.49, 28.49. HRMS: [C24H23NO3 + H]
+,
374.1751 calcd, 374.1748 found.
4-(2-Chlorophenyl)-2-oxo-N-phenethylbutanamide (34). t-Butyl
deprotection 59i: the α-ketoacid was prepared according to the general
procedure B using α-ketoester 59i (0.23 g, 0.87 mmol, 1 equiv) and
TFA (0.94 mL, 13 mmol, 15 equiv), affording the α-ketoacid 60i (0.18
g, 0.87 mmol, quant.). Amide coupling: the title compound was
prepared according to the general procedure C using the α-ketoacid 60i
(0.18 g, 0.87mmol, 1 equiv), phenethylamine (0.12mL, 0.95mmol, 1.1
equiv), HATU (0.33 g, 0.87 mmol, 1 equiv), and DiPEA (0.16 mL, 0.95
mmol, 1.1 equiv) in DCM, affording the product (0.13 g, 0.42 mmol,
48%). 1H NMR (300 MHz, CDCl3): δ 7.50−7.08 (m, 9H), 7.08−6.89
(m, 1H), 3.55 (q, J = 6.9 Hz, 2H), 3.27 (t, J = 7.5 Hz, 2H), 3.01 (t, J =
7.4 Hz, 2H), 2.84 (t, J = 7.1 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ
197.96, 159.93, 138.24, 138.01, 134.04, 130.52, 129.65, 128.82, 128.74,
127.92, 126.96, 126.82, 40.56, 36.78, 35.48, 27.23. HRMS:
[C18H18ClNO2 + H]
+, 316.1099 calcd, 316.1100 found.
4-(3-Chlorophenyl)-2-oxo-N-phenethylbutanamide (35). t-Butyl
deprotection 59j: the α-ketoacid was prepared according to the general
procedure B using α-ketoester 59j (0.55 g, 2.0 mmol, 1 equiv) and TFA
(2 mL, 26 mmol, 13 equiv), affording the α-ketoacid 60j (0.47 g, 2.0
mmol, quant.). Amide coupling: The title compound was prepared
according to the general procedure C using the α-ketoacid 60j (0.47 g,
2.0 mmol, 1 equiv), phenethylamine (0.31 mL, 2.4 mmol, 1.2 equiv),
HATU (0.84 mg, 2.2 mmol, 1.1 equiv), and DiPEA (0.42 mL, 2.4
mmol, 1.2 equiv), affording the product (0.37 g, 1.2 mmol, 53%). 1H
NMR (300 MHz, CDCl3): δ 7.73−6.73 (m, 10H), 3.58 (q, J = 6.9 Hz,
2H), 3.28 (t, J = 7.4 Hz, 2H), 3.07−2.74 (m, 4H). 13C NMR (75 MHz,
CDCl3): δ 197.71, 159.83, 142.40, 138.16, 134.13, 129.72, 128.69,
128.62, 128.53, 126.69, 126.55, 126.42, 40.47, 37.95, 35.32, 28.65.
HRMS: [C18H18ClNO2 + H]
+, 316.1099 calcd, 316.1098 found.
4-(3,4-Dichlorophenyl)-2-oxo-N-phenethylbutanamide (36). t-
Butyl deprotection 59k: the α-ketoacid was prepared according to
the general procedure B using α-ketoester 59k (90 mg, 0.30 mmol, 1
equiv) and TFA (0.25 mL, 32 mmol, 10 equiv), affording the α-
ketoacid 60k (74 mg, 0.30 mmol, quant.). Amide coupling: the title
compound was prepared according to the general procedure C using α-
ketoacid 60k (66 mg, 0.27 mmol, 1 equiv), phenethylamine (36 μL,
0.29 mmol, 1.1 equiv), HATU (110 mg, 0.29 mmol, 1.1 equiv), and
DiPEA (92 μL, 0.53 mmol, 2 equiv) in DCM, affording the product (42
mg, 0.12 mmol, 44%). 1H NMR (400 MHz, CDCl3): δ 7.41−7.32 (m,
4H), 7.32−7.26 (m, 1H), 7.22 (d, J = 7.0 Hz, 2H), 7.07 (dd, J = 8.2, 2.0
Hz, 1H), 7.05−6.97 (m, 1H), 3.60 (q, J = 7.0 Hz, 2H), 3.28 (t, J = 7.4
Hz, 2H), 3.03−2.79 (m, 4H). 13C NMR (101 MHz, CDCl3): δ 197.63,
159.85, 140.68, 138.17, 132.46, 130.53, 130.50, 130.39, 128.88, 128.76,
127.98, 126.90, 40.61, 37.94, 35.49, 28.29. HRMS: [C18H17Cl2NO2 +
H]+, 350.0709 calcd, 350.0708 found.
(E)-4-(4-Chlorophenyl)-2-oxo-N-phenethylbut-3-enamide (37).
α-Ketoacid formation: the α-ketoacid salt was prepared according to
the general procedure F using pyruvic acid (1.7 mL, 18 mmol, 1 equiv),
4-chlorobenzaldehyde (2.2 mL, 19 mmol, 1 equiv), and KOH (2.1 g, 38
mmol, 2 equiv) in MeOH, affording potassium 4-(4-chlorophenyl)-2-
oxobut-3-enoate 62a (2.0 g, 8.0 mmol, 42%). Amide coupling: the title
compound was prepared according to the general procedure F using
potassium salt 62a (2.0 g, 8.0 mmol, 1 equiv), oxalyl chloride (1.4 mL,
16 mmol, 2 equiv), phenethylamine (1.1 mL, 8.8 mmol, 1.1 equiv), and
Et3N (2.2 mL, 16 mmol, 2 equiv) in DCM, affording the product (0.30
g, 0.96 mmol, 12%). 1H NMR (300 MHz, CDCl3): δ 7.86 (d, J = 16.2
Hz, 1H), 7.73 (d, J = 16.1 Hz, 1H), 7.59 (d, J = 8.5 Hz, 2H), 7.43−7.36
(m, 2H), 7.36−7.28 (m, 2H), 7.28−7.17 (m, 4H), 3.63 (q, J = 7.0 Hz,
2H), 2.89 (t, J = 7.1 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 185.32,
161.24, 146.51, 138.34, 137.61, 132.94, 130.37, 129.48, 128.87, 128.81,




formation: the α-ketoacid salt was prepared according to the general
procedure F using pyruvic acid (0.79 mL, 11 mmol, 1 equiv),
benzaldehyde (1.2 g, 11 mmol, 1 equiv), and KOH (0.98 g, 17 mmol,
1.5 equiv) in MeOH, affording potassium 2-oxo-4-phenylbut-3-enoate
62b (0.85 g, 3.9 mmol, 36%). Amide coupling: the title compound was
prepared according to the general procedure C using potassium salt 62b
(0.20 g, 0.93 mmol, 1 equiv), phenethylamine (0.12 mL, 0.93 mmol, 1
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equiv), HCTU (0.39 g, 0.93mmol, 1 equiv), and DiPEA (0.32mL, 1.86
mmol, 2 equiv) in DMF (5 mL), affording the product (70 mg, 0.25
mmol, 27%). 1HNMR (300MHz, CDCl3): δ 7.93 (d, J = 16.2 Hz, 1H),
7.77 (d, J = 16.1 Hz, 1H), 7.71−7.62 (m, 2H), 7.49−7.37 (m, 3H),
7.36−7.16 (m, 6H), 3.63 (q, J = 7.0 Hz, 2H), 2.89 (t, J = 7.1 Hz, 2H).
13C NMR (75MHz, CDCl3): δ 185.49, 161.38, 148.12, 138.40, 134.48,
131.60, 129.28, 129.15, 128.85, 128.82, 126.83, 118.67, 40.76, 35.61.
HRMS: [C18H17NO2 + H]
+, 280.1332 calcd, 280.1331 found.
(E)-4-(4-Methoxyphenyl)-2-oxo-N-phenethylbut-3-enamide (39).
α-Ketoacid formation: the α-ketoacid salt was prepared according to
the general procedure F using sodium pyruvate (3.0 g, 27 mmol, 1
equiv), 4-methoxybenzaldehyde (3.3 mL, 27 mmol, 1 equiv), and KOH
(2.3 g, 41 mmol, 1.5 equiv) in MeOH, affording potassium 4-(4-
methoxyphenyl)-2-oxobut-3-enoate 62c (6.5 g, 27 mmol, 98%). Amide
coupling: the title compound was prepared according to the general
procedure F using potassium salt 62c (1.0 g, 4.1 mmol, 1 equiv), oxalyl
chloride (0.87 mL, 8.2 mmol, 2 equiv), phenethylamine (0.52 mL, 4.1
mmol, 1 equiv), and Et3N (1.1 mL, 8.2 mmol, 2 equiv) in DCM,
affording the product (1.2 g, 3.8 mmol, 93%). 1H NMR (400 MHz,
CDCl3): δ 7.89 (d, J = 16.0 Hz, 1H), 7.68−7.57 (m, 3H), 7.37−7.27
(m, 3H), 7.26−7.18 (m, 3H), 6.95−6.88 (m, 2H), 3.83 (s, 3H), 3.61 (q,
J = 7.0 Hz, 2H), 2.88 (t, J = 7.2 Hz, 2H). 13CNMR (101MHz, CDCl3):
δ 185.15, 162.54, 161.66, 147.93, 138.44, 131.23, 128.76, 127.27,
126.72, 116.20, 114.59, 55.50, 40.69, 35.56. HRMS: [C19H19NO3 +
H]+, 310.1438 calcd, 310.1435 found.
(E)-4-(4-Bromophenyl)-2-oxo-N-phenethylbut-3-enamide (40).
α-Ketoacid formation: the α-ketoacid salt was prepared according to
the general procedure F using pyruvic acid (1.4 mL, 16 mmol, 1 equiv),
4-bromobenzaldehyde (1.6mL, 16mmol, 1 equiv), and KOH (1.8 g, 32
mmol, 2 equiv) in MeOH, affording potassium 4-(4-bromophenyl)-2-
oxobut-3-enoate 62d (2.0 g, 6.8 mmol, 42%). Amide coupling: the title
compound was prepared according to the general procedure F using
potassium salt 62d (2.0 g, 6.8 mmol, 1 equiv), oxalyl chloride (1.2 mL,
14 mmol, 2 equiv), phenethylamine (0.94 mL, 7.5 mmol, 1.1 equiv),
and Et3N (1.90 mL, 14 mmol, 2 equiv) in DCM, affording the product
(0.84 g, 2.3 mmol, 34%). 1H NMR (300 MHz, CDCl3): δ 7.84 (d, J =
16.2 Hz, 1H), 7.74 (d, J = 16.1 Hz, 1H), 7.64−7.42 (m, 4H), 7.38−7.15
(m, 6H), 3.62 (q, J = 7.0 Hz, 2H), 2.89 (t, J = 7.1 Hz, 2H). 13C NMR
(75 MHz, CDCl3): δ 185.37, 161.22, 146.55, 138.35, 133.37, 132.45,
130.52, 128.87, 128.81, 126.86, 126.08, 119.23, 40.77, 35.60. HRMS:
[C18H16BrNO2 + H]
+, 358.0437 calcd, 358.0437 found.
(E)-4-(3-Bromophenyl)-2-oxo-N-phenethylbut-3-enamide (41).
α-Ketoacid formation: the α-ketoacid salt was prepared according to
the general procedure F using sodium pyruvate (1.0 g, 11 mmol, 1
equiv), 3-bromobenzaldehyde (1.3 mL, 11 mmol, 1 equiv), and KOH
(0.96 g, 17 mmol, 1.5 equiv) in MeOH, affording potassium 4-(3-
bromophenyl)-2-oxobut-3-enoate 62e (0.40 g, 1.4 mmol, 12%). Amide
coupling: the title compound was prepared according to the general
procedure F using potassium salt 62e (0.40 g, 1.4 mmol, 1 equiv), oxalyl
chloride (0.24 mL, 2.7 mmol, 2 equiv), phenethylamine (0.19 mL, 1.5
mmol, 1.1 equiv), and Et3N (0.38 mL, 2.7 mmol, 2 equiv) in DCM,
affording the product (0.31 g, 0.87 mmol, 62%). 1H NMR (400 MHz,
CDCl3): δ 7.86−7.78 (m, 2H), 7.74 (d, J = 16.2 Hz, 1H), 7.62−7.51
(m, 2H), 7.37−7.28 (m, 3H), 7.28−7.19 (m, 4H), 3.63 (q, J = 7.0 Hz,
2H), 2.89 (t, J = 7.1 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 185.33,
161.12, 146.13, 138.34, 136.52, 134.25, 131.84, 130.63, 128.88, 128.82,
127.72, 126.88, 123.27, 119.96, 40.78, 35.59. HRMS: [C18H16BrNO2 +
H]+, 358.0437 calcd, 358.0437 found.
(E)-4-([1,1′-Biphenyl]-3-yl)-2-oxo-N-phenethylbut-3-enamide
(42). A round-bottom flask was charged with aryl bromide 41 (0.20 g,
0.56 mmol, 1 equiv) and toluene/EtOH (4:1, 3 mL) and degassed for
20 min with sonication. Pd(PPh3)4 (13 mg, 0.01 mmol, 2 mol %),
phenylboronic acid (0.10 g, 0.84 mmol, 1.5 equiv), and K2CO3 (0.46 g,
3.4 mmol, 6 equiv) were added, and the reaction was stirred for 16 h at
80 °C. The reaction mixture was filtered over a pad of celite and
concentrated under reduced pressure. The crude residue was purified
by silica gel column chromatography (EtOAc/pentane), affording the
product (0.15 g, 0.42 mmol, 75%). 1H NMR (300 MHz, CDCl3): δ
8.03 (d, J = 16.2 Hz, 1H), 7.94−7.78 (m, 2H), 7.73−7.18 (m, 14H),
3.67 (q, J = 6.9 Hz, 2H), 2.93 (t, J = 7.1 Hz, 2H). 13C NMR (75 MHz,
CDCl3): δ 185.46, 161.38, 148.00, 142.21, 140.23, 138.39, 134.95,
130.35, 129.57, 129.02, 128.85, 128.81, 128.04, 127.94, 127.91, 127.24,




title compound was prepared according to the general procedure D
using α-ketoacid 60c (57 mg, 0.29 mmol, 1 equiv), 2-(p-tolyl)ethan-1-
amine (47 μL, 0.32mmol, 1.1 equiv), EDC·HCl (85mg, 0.44mmol, 1.5
equiv), and HOBt (60 mg, 0.44 mmol, 1.5 equiv) in DCM. Column
chromatography (2.5→ 20% EtOAc in pentane) afforded the product
(18mg, 58 μmol, 20%). 1HNMR (400MHz, CDCl3): δ 7.39−7.22 (m,
3H), 7.22−7.14 (m, 3H), 7.12 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 8.0 Hz,
2H), 7.01−6.86 (m, 1H), 3.52 (q, J = 7.0 Hz, 2H), 2.93 (t, J = 7.3 Hz,
2H), 2.80 (t, J = 7.1 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 2.32 (s, 3H), 1.93
(p, J = 7.5 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 199.02, 160.11,
141.47, 136.44, 135.16, 129.56, 128.65, 128.61, 128.56, 126.21, 126.16,
40.68, 36.24, 35.13, 24.94, 21.18. HRMS: [C20H23NO2 + H]
+,
310.1802 calcd, 310.1803 found.
N-(4-Methoxyphenethyl)-2-oxo-5-phenylpentanamide (44). The
title compound was prepared according to the general procedure D
using α-ketoacid 60c (89 mg, 0.46 mmol, 1 equiv), 2-(4-
methoxyphenyl)ethan-1-amine (75 μL, 0.51 mmol, 1.1 equiv), EDC·
HCl (0.13 g, 0.69 mmol, 1.5 equiv), and HOBt (94 mg, 0.69 mmol, 1.5
equiv) in DCM. Column chromatography (2.5 → 40% EtOAc in
pentane) afforded the product (13 mg, 40 μmol, 9%). 1H NMR (300
MHz, CDCl3): δ 7.32−7.24 (m, 2H), 7.23−7.14 (m, 3H), 7.10 (d, J =
8.6 Hz, 2H), 7.04−6.90 (m, 1H), 6.85 (d, J = 8.6 Hz, 2H), 3.79 (s, 3H),
3.50 (q, J = 6.9 Hz, 2H), 2.94 (t, J = 7.3 Hz, 2H), 2.78 (t, J = 7.1 Hz,
2H), 2.65 (t, J = 7.6 Hz, 2H), 1.93 (p, J = 7.5 Hz, 2H). 13C NMR (75
MHz, CDCl3): δ 199.03, 160.10, 158.52, 141.45, 130.25, 129.75,
128.60, 128.54, 126.15, 114.27, 55.39, 40.77, 36.23, 35.14, 34.65, 24.94.
HRMS: [C20H23NO3 + H]
+, 326.1751 calcd, 326.1752 found.
N-(3,4-Dimethoxyphenethyl)-2-oxo-5-phenylpentanamide (45).
The title compound was prepared according to the general procedure
D using α-ketoacid 60c (57 mg, 0.30 mmol, 1 equiv), 2-(3,4-
dimethoxyphenyl)ethan-1-amine (56 μL, 0.33 mmol, 1.1 equiv), EDC·
HCl (86 mg, 0.45 mmol, 1.5 equiv), and HOBt (61 mg, 0.45 mmol, 1.5
equiv) in DCM. Column chromatography (2.5 → 40% EtOAc in
pentane) afforded the product (6 mg, 17 μmol, 6%). 1H NMR (400
MHz, CDCl3): δ 7.31−7.26 (m, 2H), 7.22−7.11 (m, 3H), 7.03−6.91
(m, 1H), 6.81 (d, J = 8.1 Hz, 1H), 6.77−6.66 (m, 2H), 3.87 (s, 3H),
3.86 (s, 3H), 3.52 (q, J = 7.0 Hz, 2H), 2.94 (t, J = 7.3 Hz, 2H), 2.78 (t, J
= 7.1 Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 1.93 (p, J = 7.5 Hz, 2H). 13C
NMR (75 MHz, CDCl3): δ 199.04, 160.13, 149.01, 147.96, 141.44,
130.77, 128.56, 126.17, 120.73, 111.86, 111.53, 56.02, 40.69, 36.25,
35.16, 24.95. HRMS: [C21H25NO4 + H]
+, 356.1856 calcd, 356.1858
found.
N-(4-Hydroxyphenethyl)-2-oxo-5-phenylpentanamide (46). The
title compound was prepared according to the general procedure D
using α-ketoacid 60c (98 mg, 0.51 mmol, 1 equiv), 4-(2-aminoethyl)-
phenol (77 mg, 0.56 mmol, 1.1 equiv), EDC·HCl (0.15 g, 0.77 mmol,
1.5 equiv), and HOBt (0.10 g, 0.77 mmol, 1.5 equiv) in DCM. Column
chromatography (10 → 60% EtOAc in pentane) afforded the product
(18mg, 58 μmol, 20%). 1HNMR (400MHz, CDCl3): δ 7.32−7.23 (m,
2H), 7.23−7.12 (m, 3H), 7.04 (d, J = 8.5 Hz, 2H), 7.01−6.90 (m, 1H),
6.83−6.72 (m, 2H), 5.26 (br s, 1H), 3.50 (q, J = 7.0Hz, 2H), 2.93 (t, J =
7.3 Hz, 2H), 2.76 (t, J = 7.1 Hz, 2H), 2.64 (t, J = 7.6 Hz, 2H), 1.93 (p, J
= 7.5 Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 198.97, 160.18, 154.71,
141.43, 130.14, 129.92, 128.61, 128.55, 126.16, 115.75, 40.84, 36.27,




title compound was prepared according to the general procedure D
using α-ketoacid 60c (0.96 g, 5.0 mmol, 1 equiv), 2-(4-bromophenyl)-
ethan-1-amine (0.85 mL, 5.5 mmol, 1.1 equiv), EDC·HCl (1.5 g, 7.5
mmol, 1.5 equiv), HOBt (1.2 g, 7.5 mmol, 1.5 equiv), and Et3N (1.4
mL, 10 mmol, 2.0 equiv) in DCM. Column chromatography (2.5 →
20%EtOAc in pentane) afforded the product (0.28 g, 0.74mmol, 15%).
1HNMR (400MHz, CDCl3): δ 7.41 (d, J = 7.6Hz, 2H), 7.32−7.22 (m,
2H), 7.22−7.12 (m, 3H), 7.04 (d, J = 7.8 Hz, 2H), 7.02−6.95 (m, 1H),
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3.50 (q, J = 6.8 Hz, 2H), 2.92 (t, J = 7.2 Hz, 2H), 2.78 (t, J = 7.1 Hz,
2H), 2.64 (t, J = 7.5 Hz, 2H), 1.92 (p, J = 7.3 Hz, 2H). 13C NMR (101
MHz, CDCl3): δ 198.86, 160.13, 141.35, 137.23, 131.87, 130.47,
128.55, 128.51, 126.12, 120.68, 40.31, 36.18, 35.07, 34.91, 24.87.
HRMS: [C19H20NBrO2 + H]
+, 374.0750 calcd, 374.0751 found.
N-(3-Chlorophenethyl)-2-oxo-5-phenylpentanamide (48). The
title compound was prepared according to the general procedure D
using α-ketoacid 60c (72mg, 0.37 mmol, 1 equiv), 2-(3-chlorophenyl)-
ethan-1-amine (57 μL, 0.41 mmol, 1.1 equiv), EDC·HCl (0.11 g, 0.56
mmol, 1.5 equiv), and HOBt (86 mg, 0.56 mmol, 1.5 equiv) in DCM.
Column chromatography (2.5→ 40% EtOAc in pentane) afforded the
product (29mg, 87 μmol, 24%). 1HNMR (400MHz, CDCl3): δ 7.33−
7.13 (m, 8H), 7.11−7.02 (m, 1H), 7.02−6.90 (m, 1H), 3.53 (q, J = 6.8
Hz, 2H), 2.93 (t, J = 7.3Hz, 2H), 2.82 (t, J = 7.2Hz, 2H), 2.65 (t, J = 7.6
Hz, 2H), 1.94 (p, J = 7.5 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ
198.91, 165.51, 140.31, 130.11, 128.94, 128.61, 128.56, 127.12, 126.97,
126.17, 40.35, 36.23, 35.24, 35.15, 24.95. HRMS: [C19H20ClNO2 +
H]+, 330.1255 calcd, 330.1256 found.
N-(2-Chlorophenethyl)-2-oxo-5-phenylpentanamide (49). The
title compound was prepared according to the general procedure D
using α-ketoacid 60c (81mg, 0.42 mmol, 1 equiv), 2-(2-chlorophenyl)-
ethan-1-amine (66 μL, 0.47 mmol, 1.1 equiv), EDC·HCl (0.12 g, 0.64
mmol, 1.5 equiv), and HOBt (86 mg, 0.64 mmol, 1.5 equiv) in DCM.
Column chromatography (2.5→ 20% EtOAc in pentane) afforded the
product (11 mg, 32 μmol, 8%). 1H NMR (400 MHz, CDCl3): δ 7.41−
7.32 (m, 1H), 7.32−7.26 (m, 2H), 7.24−7.08 (m, 6H), 7.07−6.91 (m,
1H), 3.57 (q, J = 6.9 Hz, 2H), 2.99 (t, J = 7.1 Hz, 2H), 2.93 (t, J = 7.3
Hz, 2H), 2.65 (t, J = 7.6 Hz, 2H), 1.93 (p, J = 7.4 Hz, 2H). 13C NMR
(75 MHz, CDCl3): δ 198.96, 160.23, 141.45, 136.03, 134.27, 131.00,
129.90, 128.63, 128.56, 128.45, 127.23, 126.17, 39.08, 36.23, 35.15,
33.30, 24.96. HRMS: [C19H20ClNO2 + H]
+, 330.1255 calcd, 330.1256
found.
N-(2,4-Dichlorophenethyl)-2-oxo-5-phenylpentanamide (50).
The title compound was prepared according to the general procedure
D using α-ketoacid 60c (95 mg, 0.49 mmol, 1 equiv), 2-(2,4-
dichlorophenyl)ethan-1-amine (89 μL, 0.54 mmol, 1.1 equiv), EDC·
HCl (0.14 g, 0.74 mmol, 1.5 equiv), and HOBt (0.10 g, 0.74 mmol, 1.5
equiv) in DCM. Column chromatography (2.5 → 40% EtOAc in
pentane) afforded the product (14 mg, 38 μmol, 8%). 1H NMR (400
MHz, CDCl3): δ 7.38 (s, 1H), 7.32−7.26 (m, 2H), 7.23−7.15 (m, 4H),
7.15−7.10 (m, 1H), 7.07−6.87 (m, 1H), 3.54 (q, J = 6.8 Hz, 2H), 2.94
(q, J = 7.5Hz, 4H), 2.65 (t, J = 7.6Hz, 2H), 1.94 (p, J = 7.4Hz, 2H). 13C
NMR (101 MHz, CDCl3): δ 198.87, 160.25, 141.40, 134.92, 134.63,
133.46, 131.72, 129.68, 128.61, 128.56, 127.50, 126.18, 38.91, 36.21,




301). The title compound was prepared according to the general
procedure D using α-ketoacid 60c (0.19 g, 1.0 mmol, 1 equiv), 2-(4-
phenoxyphenyl)ethan-1-amine TFA salt (0.36 g, 1.1 mmol, 1.1 equiv),
EDC·HCl (0.29 g, 1.5 mmol, 1.5 equiv), HOBt (0.23 g, 1.5 mmol, 1.5
equiv), and Et3N (0.28 mL, 2.0 mmol, 2.0 equiv) in DCM. Column
chromatography (2.5→ 20% EtOAc in pentane) afforded the product
(32 mg, 86 μmol, 9%). 1H NMR (400 MHz, CDCl3): δ 7.36−7.24 (m,
4H), 7.22−7.06 (m, 6H), 7.04−6.91 (m, 5H), 3.53 (q, J = 6.7 Hz, 2H),
2.94 (t, J = 7.2Hz, 2H), 2.81 (t, J = 7.1Hz, 2H), 2.65 (t, J = 7.5 Hz, 2H),
1.94 (p, J = 7.4 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 199.01,
160.14, 157.33, 156.18, 141.42, 133.07, 130.04, 129.86, 128.60, 128.55,
126.16, 123.36, 119.24, 118.95, 40.68, 36.23, 35.13, 34.82, 24.93.
HRMS: [C25H25NO3 + H]
+, 388.1907 calcd, 388.1909 found.
2-Oxo-5-phenyl-N-(4-(pyrazin-2-yloxy)phenethyl)pentanamide
(52). Boc-deprotection 65a: a round-bottom flask was charged with
Boc-protected amine 65a (0.32 g, 1.0 mmol, 1 equiv) and HCl (4 M in
dioxane, 4.5 mL, 18 mmol, 18 equiv). After stirring for 1 h, the mixture
was concentrated under reduced pressure and coevaporated with
toluene (3×), which afforded the deprotected amine 66a as theHCl salt
(0.25 g, 1.0 mmol, quant.). Amide coupling: the title compound was
prepared according to the general procedure D using the α-ketoacid
60c (38 mg, 0.20 mmol, 1 equiv), EDC·HCl (46 mg, 0.24 mmol, 1.2
equiv), HOBt (32 mg, 0.24 mmol, 1.2 equiv), NMM (87 μL, 0.80
mmol, 4 equiv), and the amine HCl salt 66a (60 mg, 0.24 mmol, 1.2
equiv). Column chromatography (30 → 70% EtOAc in pentane)
afforded the product (23 mg, 59 μmol, 30%). 1H NMR (400 MHz,
CDCl3): δ 8.43 (d, J = 1.3 Hz, 1H), 8.26 (d, J = 2.7 Hz, 1H), 8.10 (dd, J
= 2.7, 1.4 Hz, 1H), 7.33−7.22 (m, 4H), 7.22−7.15 (m, 3H), 7.14−7.08
(m, 2H), 7.07−6.98 (m, 1H), 3.57 (q, J = 7.0 Hz, 2H), 2.95 (t, J = 7.3
Hz, 2H), 2.87 (t, J = 7.2 Hz, 2H), 2.66 (t, J = 7.6 Hz, 2H), 1.94 (p, J =
7.4 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 198.97, 160.17, 151.83,
141.42, 141.17, 138.62, 136.08, 135.48, 130.17, 128.60, 128.54, 126.16,
121.66, 40.54, 36.23, 35.13, 35.01, 24.92. HRMS: [C23H23N3O3 + H]
+,
390.1812 calcd, 390.1823 found.
2-Oxo-5-phenyl -N-(4- (pyr imidin-2-y loxy)phenethyl ) -
pentanamide (53). Boc-deprotection 65b: a round-bottom flask was
charged with Boc-protected amine 65b (0.30 g, 0.94 mmol, 1 equiv)
and HCl (4M in dioxane, 4.5 mL, 18 mmol, 19 equiv). After stirring for
1 h, the mixture was concentrated under reduced pressure and
coevaporated with toluene (3×), which afforded the deprotected amine
66b as the HCl salt (0.24 g, 0.94 mmol, quant.). Amide coupling: the
title compound was prepared according to the general procedure D
using α-ketoacid 60c (38 mg, 0.20 mmol, 1 equiv), EDC·HCl (46 mg,
0.24 mmol, 1.2 equiv), HOBt (32 mg, 0.24 mmol, 1.2 equiv), NMM
(87 μL, 0.80 mmol, 4 equiv), and the amine HCl salt 66b (76 mg, 0.24
mmol, 1.2 equiv). Purification by preparative HPLC (C18 reverse
phase, 45−55% ACN/H2O + 0.2% TFA, RT 10.86 min) afforded the
product (12 mg, 31 μmol, 15%). 1H NMR (400 MHz, CDCl3): δ 8.56
(d, J = 4.8 Hz, 2H), 7.33−7.22 (m, 4H), 7.22−7.12 (m, 5H), 7.04 (t, J =
4.8 Hz, 2H), 3.57 (q, J = 6.9 Hz, 2H), 2.95 (t, J = 7.3 Hz, 2H), 2.87 (t, J
= 7.2 Hz, 2H), 2.66 (t, J = 7.6 Hz, 2H), 1.95 (p, J = 7.4 Hz, 2H). 13C
NMR (101 MHz, CDCl3): δ 198.96, 165.46, 160.19, 159.86, 151.70,
141.43, 135.50, 130.02, 128.61, 128.54, 126.15, 122.03, 116.32, 40.54,




phenethyl)pentanamide (54). Boc-deprotection 65c: a round-bottom
flask was charged with Boc-protected amine 65c (0.18 g, 0.48 mmol, 1
equiv) and HCl (4 M in dioxane, 3 mL, 12 mmol, 25 equiv). After
stirring for 1 h, the mixture was concentrated under reduced pressure
and coevaporated with toluene (3×), which afforded the deprotected
amine 66c as the HCl salt (0.15 g, 0.48 mmol, quant.). Amide coupling:
the title compound was prepared according to the general procedure D
using the α-ketoacid 60c (38 mg, 0.20 mmol, 1 equiv), EDC·HCl (46
mg, 0.24 mmol, 1.2 equiv), HOBt (32 mg, 0.24 mmol, 1.2 equiv),
NMM(87 μL, 0.80mmol, 4 equiv), and the amineHCl salt 66c (68mg,
0.24 mmol, 1.2 equiv). Purification by preparative HPLC (C18 reverse
phase, 65−75% ACN/H2O + 0.2% TFA, RT 8.55 min) afforded the
product (21 mg, 46 μmol, 23%). 1H NMR (400 MHz, CDCl3): δ 8.46
(d, J = 2.7 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.34−7.22 (m, 5H), 7.21−
7.15 (m, 3H), 7.07−6.95 (m, 3H), 3.56 (q, J = 6.9 Hz, 2H), 2.95 (t, J =
7.3 Hz, 2H), 2.87 (t, J = 7.2 Hz, 2H), 2.69−2.62 (m, 2H), 1.94 (p, J =
7.5 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ 198.97, 160.15, 156.50,
153.74, 142.12 (q, J = 35.1 Hz), 141.38, 140.89, 135.45, 130.69, 128.60,
128.56, 126.18, 124.53, 124.08 (q, J = 209.2 Hz), 121.63 (q, J = 2.7 Hz),
120.28, 40.55, 36.23, 35.12, 34.92, 24.93. HRMS: [C25H23F3N2O3 +
H]+, 457.1734 calcd, 457.1743 found.
2-Oxo-5-phenyl-N-(4-((5-(trifluoromethyl)pyridin-2-yl)oxy)-
phenethyl)pentanamide (55). Boc-deprotection 65d: a round-bottom
flask was charged with Boc-protected amine 65d (0.19 g, 0.50 mmol, 1
equiv) and HCl (4 M in dioxane, 4.5 mL, 18 mmol, 36 equiv). After
stirring for 1 h, the mixture was concentrated under reduced pressure
and coevaporated with toluene (3×), which afforded the deprotected
amine 66d as the HCl salt (0.16 g, 0.50 mmol, quant.). Amide coupling:
the title compound was prepared according to the general procedure D
using the α-ketoacid 60c (38 mg, 0.20 mmol, 1 equiv), EDC·HCl (46
mg, 0.24 mmol, 1.2 equiv), HOBt (32 mg, 0.24 mmol, 1.2 equiv),
NMM (87 μL, 0.80 mmol, 4 equiv), and the amine HCl salt 66d (76
mg, 0.24 mmol, 1.2 equiv). Purification by preparative HPLC (C18
reverse phase, 55−65%ACN/H2O + 0.2%TFA, RT 8.74min) afforded
the product (26 mg, 57 μmol, 28%). 1H NMR (400 MHz, CDCl3): δ
8.51−8.37 (m, 1H), 7.90 (dd, J = 8.7, 2.3 Hz, 1H), 7.32−7.22 (m, 4H),
7.22−7.15 (m, 3H), 7.13−7.07 (m, 2H), 7.07−6.98 (m, 2H), 3.57 (q, J
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= 7.0 Hz, 2H), 2.95 (t, J = 7.3 Hz, 2H), 2.87 (t, J = 7.2 Hz, 2H), 2.74−
2.59 (m, 2H), 1.94 (p, J = 7.5 Hz, 2H). 13CNMR (101MHz, CDCl3): δ
198.97, 165.88, 160.18, 151.99, 145.56 (q, J = 4.3 Hz), 141.41, 136.85
(q, J = 3.2 Hz), 135.52, 130.17, 128.60, 128.55, 126.16, 123.79 (q, J =
271.4 Hz), 121.86, 121.49, 111.52, 40.54, 36.24, 35.13, 35.01, 24.93.
HRMS: [C25H23F3N2O3 + H]
+, 457.1734 calcd, 457.1746 found.
N-(4-((4-Chloropyrimidin-2-yl)oxy)phenethyl)-2-oxo-5-phenyl
Pentanamide (56). Boc-deprotection 65e: a round-bottom flask was
charged with Boc-protected amine 65e (0.18 g, 0.50 mmol, 1 equiv)
and HCl (4M in dioxane, 3 mL, 12 mmol, 24 equiv). After stirring for 1
h, the mixture was concentrated under reduced pressure and
coevaporated with toluene (3×), which afforded the deprotected
amine 66e as the HCl salt (0.14 g, 0.50 mmol, quant.). Amide coupling:
the title compound was prepared according to the general procedure D
using the α-ketoacid 60c (38 mg, 0.20 mmol, 1 equiv), EDC·HCl (46
mg, 0.24 mmol, 1.2 equiv), HOBt (32 mg, 0.24 mmol, 1.2 equiv),
NMM(87 μL, 0.80mmol, 4 equiv), and the amineHCl salt 66e (60mg,
0.24 mmol, 1.2 equiv). Purification by preparative HPLC (C18 reverse
phase, 50% to 60% ACN/H2O + 0.2% TFA, RT 10.44 min) afforded
the product (20 mg, 47 μmol, 24%). 1H NMR (400 MHz, CDCl3): δ
8.43 (d, J = 5.7 Hz, 1H), 7.32−7.22 (m, 4H), 7.22−7.14 (m, 3H),
7.14−7.07 (m, 2H), 7.04 (t, J = 5.7 Hz, 1H), 6.78 (d, J = 5.7 Hz, 1H),
3.57 (q, J = 6.9 Hz, 2H), 2.95 (t, J = 7.3 Hz, 2H), 2.88 (t, J = 7.2 Hz,
2H), 2.70−2.60 (m, 2H), 1.94 (p, J = 7.5 Hz, 2H). 13C NMR (101
MHz, CDCl3): δ 198.95, 170.46, 160.74, 160.38, 160.18, 150.64,
141.39, 136.40, 130.27, 128.59, 128.54, 126.16, 121.62, 106.77, 40.51,
36.23, 35.12, 35.01, 24.92. HRMS: [C23H22ClN3O3 + Na]
+, 446.1242
calcd, 446.1274 found.
tert-Butyl 2-(Methoxyamino)-2-oxoacetate (58). Literature pro-
cedure:43 a round-bottom flask was charged with oxalyl chloride (13.5
mL, 158 mmol, 1 equiv) in dry THF (200 mL) under an inert
atmosphere and was cooled to 0 °C. tert-Butanol (14.7 mL, 154 mmol,
0.975 equiv) was added in one batch, and the mixture was stirred for 1 h
at 0 °C. N,O-Dimethylhydroxylamine hydrochloride (15.4 g, 158
mmol, 1 equiv) was added to the reactionmixture followed by Et3N (66
mL, 472 mmol, 3 equiv). The reaction mixture was stirred for 2 h at 0
°C, followed by quenching with H2O (200 mL). The aqueous layer was
extracted with EtOAc (2× 200mL). The combined organic layers were
washed with sat. aq NaHCO3 (2 × 200 mL) and brine (1 × 200 mL),
dried (MgSO4), filtered, and concentrated under reduced pressure. The
crude residue was purified using silica gel column chromatography (0
→ 20% EtOAc in pentane), affording the product (22.3 g, 117 mmol,
75%). 1H NMR (300 MHz, CDCl3): δ 3.76 (s, 3H), 3.20 (s, 3H), 1.56
(s, 9H). 13C NMR (75 MHz, CDCl3): δ 161.98, 161.63, 83.89, 61.82,
30.88, 27.62.
tert-Butyl 4-(4-Chlorophenyl)-2-oxobutanoate (59a). The title
compound was prepared according to the general procedure A using
magnesium (0.42 g, 18.3 mmol, 2.0 equiv), 1-(2-bromoethyl)-4-
chlorobenzene (1.3 mL, 9.1 mmol, 1 equiv), and Weinreb amide 58
(1.7 g, 9.1 mmol, 1.0 equiv), affording the product (0.85 g, 3.2 mmol,
35%). 1HNMR (300MHz, CDCl3): δ 7.24 (d, J = 8.4 Hz, 2H), 7.14 (d,
J = 8.4Hz, 2H), 3.10 (t, J = 7.3Hz, 2H), 2.90 (t, J = 7.4Hz, 2H), 1.53 (s,
9H). 13C NMR (75 MHz, CDCl3): δ 194.31, 160.25, 138.78, 132.05,
129.84, 128.63, 84.12, 40.57, 28.42, 27.78.
tert-Butyl 2-Oxo-4-phenylbutanoate (59b). The title compound
was prepared according to the general procedure A using magnesium
(72 mg, 3.0 mmol, 0.7 equiv), (2-bromoethyl)benzene (0.58 mL, 4.2
mmol, 1 equiv), and Weinreb amide 58 (0.80 g, 4.2 mmol, 1 equiv),
affording the product (0.22 g, 0.95 mmol, 22%). 1H NMR (400 MHz,
CDCl3): δ 7.33−7.25 (m, 2H), 7.25−7.09 (m, 3H), 3.15−3.06 (m,
2H), 2.93 (t, J = 7.5 Hz, 2H), 1.53 (s, 9H). 13C NMR (101 MHz,
CDCl3): δ 194.74, 160.47, 140.38, 128.65, 128.49, 126.40, 84.11, 40.92,
29.20, 27.88.
tert-Butyl 2-Oxo-5-phenylpentanoate (59c). The title compound
was prepared according to the general procedure A using magnesium
(2.3 g, 94 mmol, 2.0 equiv), (3-bromopropyl)benzene (11 mL, 71
mmol, 1.5 equiv) and Weinreb amide 58 (8.9 g, 47 mmol, 1.0 equiv).
Column chromatography (0 → 10% EtOAc in pentane) afforded the
product (7.4 g, 30 mmol, 64%). 1H NMR (300 MHz, CDCl3): δ 7.34−
7.21 (m, 2H), 7.16 (t, J = 7.1 Hz, 3H), 2.76 (t, J = 7.3 Hz, 2H), 2.63 (t, J
= 7.6 Hz, 2H), 1.92 (p, J = 7.4 Hz, 2H), 1.51 (s, 9H). 13C NMR (75
MHz, CDCl3): δ 195.22, 160.57, 141.16, 128.34, 125.95, 83.65, 38.21,
34.75, 27.66, 24.56.
tert-Butyl 4-(2-Chlorophenyl)-2-oxobutanoate (59d). The title
compound was prepared according to the general procedure A using
magnesium (0.17 g, 7.0 mmol, 2 equiv), (4-bromobutyl)benzene (0.62
mL, 3.5 mmol, 1 equiv), and Weinreb amide 58 (0.67 g, 3.5 mmol, 1
equiv), affording the product (0.33 g, 1.3 mmol, 36%). 1H NMR (400
MHz, CDCl3): δ 7.29−7.20 (m, 2H), 7.20−7.10 (m, 3H), 2.83−2.70
(m, 2H), 2.66−2.55 (m, 2H), 1.71−1.57 (m, 4H), 1.51 (s, 9H). 13C
NMR (101 MHz, CDCl3): δ 195.46, 160.77, 141.94, 128.36, 128.31,
125.79, 83.76, 38.89, 35.59, 30.69, 27.77, 22.64.
tert-Butyl 2-Oxo-2-phenylacetate (59e). The title compound was
prepared according to the general procedure A using magnesium (0.21
g, 8.5 mmol, 2 equiv), bromobenzene (0.43 mL, 4.2 mmol, 1 equiv),
and Weinreb amide 58 (0.80 g, 4.2 mmol, 1 equiv), affording the
product (0.73 g, 3.5 mmol, 83%). 1H NMR (400 MHz, MeOD): δ
7.97−7.87 (m, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 2H),
1.55 (s, 9H). 13C NMR (101 MHz, MeOD): δ 187.86, 164.89, 135.68,
133.15, 130.42, 129.84, 85.53, 85.32, 28.22.
tert-Butyl 2-Oxo-4-(p-tolyl)butanoate (59f). The title compound
was prepared according to the general procedure A using magnesium
(0.24 g, 10 mmol, 2 equiv), 1-(2-bromoethyl)-4-methylbenzene (0.77
mL, 5.0 mmol, 1 equiv), and Weinreb amide 58 (0.95 g, 5.0 mmol, 1
equiv), affording the product (0.54 g, 2.2 mmol, 44%). 1H NMR (400
MHz, CDCl3): δ 7.09−7.03 (m, 4H), 3.10−3.01 (m, 2H), 2.86 (t, J =
7.5 Hz, 2H), 2.28 (s, 3H), 1.50 (s, 9H). 13C NMR (101 MHz, CDCl3):
δ 194.42, 160.24, 137.09, 135.51, 129.06, 128.13, 83.59, 40.81, 28.54,
27.58.
tert-Butyl 2-Oxo-4-(4-(trifluoromethyl)phenyl)butanoate (59g).
The title compound was prepared according to the general procedure A
using magnesium (0.18 g, 7.9 mmol, 2 equiv), 1-(2-bromoethyl)-4-
(trifluoromethyl)benzene (0.67 mL, 4.0 mmol, 1 equiv), and Weinreb
amide 58 (0.75 g, 4.0 mmol, 1 equiv), affording the product (0.21 g,
0.83 mmol, 21%). 1H NMR (300 MHz, CDCl3): δ 7.53 (d, J = 8.1 Hz,
2H), 7.33 (d, J = 8.0 Hz, 2H), 3.25−3.09 (m, 2H), 2.99 (t, J = 7.3 Hz,
2H), 1.53 (s, 9H). 13C NMR (75 MHz, CDCl3): δ 194.12, 160.18,
144.54 (q, J = 1.1 Hz), 128.86, 128.67 (q, J = 36.7 Hz), 125.45 (q, J =
3.8 Hz), 124.30 (q, J = 272.0 Hz), 84.21, 40.27, 28.83, 27.70.
tert-Butyl 4-(4-Fluorophenyl)-2-oxobutanoate (59h). The title
compound was prepared according to the general procedure A using
magnesium (0.24 g, 10.6 mmol, 2 equiv), 1-(2-bromoethyl)-4-
fluorobenzene (0.72 mL, 5.3 mmol, 1 equiv), and Weinreb amide 59
(1.1 g, 5.3 mmol, 1 equiv), affording the product (0.28 g, 1.1 mmol,
21%). 1H NMR (400 MHz, CDCl3): δ 7.23−7.07 (m, 2H), 7.04−6.88
(m, 2H), 3.09 (t, J = 7.5 Hz, 2H), 2.91 (t, J = 7.4 Hz, 2H), 1.53 (s, 9H).
13CNMR (101MHz, CDCl3): δ 194.55, 162.77, 160.37 (d, J = 5.3 Hz),
136.00 (d, J = 3.2 Hz), 129.93 (d, J = 7.8 Hz), 115.37 (d, J = 21.2 Hz),
84.18, 40.90, 28.37, 27.85.
tert-Butyl 4-(2-Chlorophenyl)-2-oxobutanoate (59i). The title
compound was prepared according to the general procedure A using
magnesium (0.22 g, 9.1 mmol, 2 equiv), 1-(2-bromoethyl)-2-
chlorobenzene (0.69 mL, 4.6 mmol, 1 equiv), and Weinreb amide 58
(0.86 g, 4.6 mmol, 1 equiv), affording the product (0.34 g, 1.3 mmol,
28%). 1H NMR (400 MHz, CDCl3): δ 7.32 (dd, J = 7.4, 1.8 Hz, 1H),
7.25 (dd, J = 7.2, 2.1 Hz, 1H), 7.20−7.10 (m, 2H), 3.21−3.07 (m, 2H),
3.08−2.97 (m, 2H), 1.52 (s, 9H). 13C NMR (101 MHz, CDCl3): δ
194.24, 160.12, 137.77, 133.79, 130.64, 129.48, 127.86, 126.93, 83.90,
38.87, 27.68, 27.14.
tert-Butyl 4-(3-Chlorophenyl)-2-oxobutanoate (59j). The title
compound was prepared according to the general procedure A using
magnesium (0.22 g, 9.1 mmol, 2 equiv), 1-(2-bromoethyl)-3-
chlorobenzene (0.67 mL, 4.6 mmol, 1 equiv), and Weinreb amide 58
(0.86 g, 4.6 mmol, 1 equiv), affording the product (0.51 g, 1.9 mmol,
42%). 1H NMR (400 MHz, CDCl3): δ 7.24−7.11 (m, 3H), 7.11−7.03
(m, 1H), 3.10 (t, J = 7.5 Hz, 2H), 2.89 (t, J = 7.5 Hz, 2H), 1.52 (s, 9H).
13C NMR (101 MHz, CDCl3): δ 194.02, 160.08, 142.29, 134.06,
129.73, 128.45, 126.61, 126.38, 83.92, 40.29, 28.59, 27.64.
tert-Butyl 4-(3,4-Dichlorophenyl)-2-oxobutanoate (59k).The title
compound was prepared according to the general procedure A using
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.0c00522
J. Med. Chem. 2020, 63, 9340−9359
9355
magnesium (34 mg, 1.4 mmol, 1.2 equiv), 4-(2-bromoethyl)-1,2-
dichlorobenzene (0.30 g, 1.2 mmol, 1 equiv), and Weinreb amide 58
(0.27 g, 1.4 mmol, 1.2 equiv), affording the product (90mg, 0.30 mmol,
25%). 1H NMR (400 MHz, CDCl3): δ 7.43−7.22 (m, 2H), 7.05 (dd, J
= 8.2, 1.6 Hz, 1H), 3.10 (t, J = 7.4Hz, 2H), 2.89 (t, J = 7.4Hz, 2H), 1.54
(s, 9H). 13C NMR (101 MHz, CDCl3): δ 194.04, 160.22, 140.61,
132.46, 130.65, 130.53, 130.52, 128.06, 84.36, 40.28, 28.23, 27.86.
2-Oxo-5-phenylpentanoic Acid (60c). The title compound was
prepared according to the general procedure B using α-ketoester 59c
(7.4 g, 30 mmol, 1 equiv) and TFA (23 mL, 300 mmol, 10 equiv),
affording the product (5.8 g, 30 mmol, quant.). 1H NMR (400 MHz,
CDCl3): δ 7.33−7.12 (m, 5H), 2.91 (t, J = 7.2 Hz, 2H), 2.66 (t, J = 7.5
Hz, 2H), 1.98 (p, J = 7.4 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ
195.53, 160.50, 140.94, 128.63, 128.56, 126.32, 37.15, 34.86, 24.66.
HRMS: [C11H12O3 + H]
+, 193.0859 calcd, 193.0859 found.
N-Boc-tyramine (64). A round-bottom flask was charged with
tyramine (5.0 g, 36 mmol, 1.0 equiv) and dissolved in THF (160 mL).
Boc2O (8.1 g, 37mmol, 1.0 equiv) and a solution of NaHCO3 (3.4 g, 40
mmol, 1.1 equiv) in water (80 mL) were added, and the reaction was
stirred vigorously overnight. The mixture was then extracted with Et2O
(3 × 50 mL), and the combined organic layers were sequentially
washedwith 0.1MHCl (1× 100mL), water (1× 100mL) and brine (1
× 100 mL), dried over MgSO4, filtered, and concentrated under
reduced pressure. Purification by silica gel column chromatography (10
→ 40%EtOAc in pentane) afforded the product (9.1 g, 31mmol, 85%).
1H NMR (400 MHz, CDCl3): δ 7.65 (br s, 1H), 6.98 (d, J = 7.8 Hz,
2H), 6.80 (d, J = 8.0 Hz, 2H), 4.92−4.47 (m, 1H), 3.46−3.17 (m, 2H),
2.77−2.56 (m, 2H), 1.44 (s, 9H). 13C NMR (101 MHz, CDCl3): δ
156.53, 155.06, 130.01, 129.81, 115.61, 79.87, 42.14, 35.22, 28.48.
HRMS: [C13H19NO3 + Na]
+, 260.1257 calcd, 260.1253 found.
tert-Butyl (4-(Pyrazin-2-yloxy)phenethyl)carbamate (65a). The
title compound was prepared according to the general procedure E
usingN-Boc-tyramine 64 (0.48 g, 2.0 mmol, 1 equiv), 2-chloropyrazine
(0.18 mL, 2.0 mmol, 1 equiv) and K2CO3 (0.55 g, 4.0 mmol, 2 equiv) in
DMSO (2 mL). Column chromatography (20 → 60% EtOAc/
pentane) afforded the product (0.50 g, 1.6 mmol, 79%). 1H NMR (300
MHz, CDCl3): δ 8.40 (s, 1H), 8.23 (s, 1H), 8.08 (s, 1H), 7.25 (d, J = 8.0
Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 5.14−4.70 (m, 1H), 3.58−3.20 (m,
2H), 2.82 (t, J = 6.8 Hz, 2H), 1.44 (s, 9H). 13C NMR (75 MHz,
CDCl3): δ 160.04, 155.80, 151.32, 140.91, 138.28, 136.15, 135.74,
130.02, 121.16, 78.97, 41.62, 35.53, 28.31. HRMS: [C17H21N3O3 +
Na]+, 338.1475 calcd, 338.1469 found.
tert-Butyl(4-(pyrimidin-2-yloxy)phenethyl)carbamate (65b). The
title compound was prepared according to the general procedure E
using N-Boc-tyramine 64 (0.48 g, 2 mmol, 1 equiv), 2-chloro-
pyrimidine (0.23 g, 2 mmol, 1 equiv) and K2CO3 (0.55 g, 4 mmol, 2
equiv) in DMSO (2 mL). Column chromatography (40 → 70%
EtOAc/pentane) afforded the product (0.52 g, 1.7 mmol, 83%). 1H
NMR (300 MHz, CDCl3): δ 8.56 (d, J = 4.8 Hz, 2H), 7.31−7.19 (m,
2H), 7.14 (d, J = 8.4 Hz, 2H), 7.04 (t, J = 4.8 Hz, 1H), 4.84−4.29 (m,
1H), 3.40 (q, J = 6.3 Hz, 2H), 2.82 (t, J = 6.9 Hz, 2H), 1.44 (s, 9H). 13C
NMR (75 MHz, CDCl3): δ 165.60, 159.82, 155.95, 151.48, 136.25,
130.10, 121.77, 116.23, 79.26, 41.74, 35.75, 28.51. HRMS:
[C17H21N3O3 + H]
+, 316.1656 calcd, 316.1653 found.
tert-Butyl(4-((6-(trifluoromethyl)pyridin-3-yl)oxy)phenethyl)-
carbamate (65c). The title compound was prepared according to the
general procedure E usingN-Boc-tyramine 64 (0.25 g, 1.05 mmol, 1.05
equiv), 2-trifluoromethyl-5-fluoropyridine (0.12 mL, 1 mmol, 1 equiv),
and K2CO3 (0.21 g, 1.5 mmol, 1.5 equiv) in DMF (5 mL). Column
chromatography (10 → 40% EtOAc/pentane) afforded the product
(0.28 g, 0.73 mmol, 73%). 1H NMR (300 MHz, CDCl3): δ 8.46 (d, J =
2.6 Hz, 1H), 7.61 (d, J = 8.7 Hz, 1H), 7.45−7.15 (m, 3H), 7.02 (d, J =
8.5 Hz, 2H), 4.89−4.35 (m, 1H), 3.39 (q, J = 6.6 Hz, 2H), 2.82 (t, J =
7.1 Hz, 2H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3): δ 156.60,
155.96, 153.40, 140.77, 136.36, 130.76, 124.35, 121.54, 120.10, 79.38,




carbamate (65d). The title compound was prepared according to the
general procedure E using N-Boc-tyramine 64 (0.24 g, 1.0 mmol, 1
equiv), 2-chloro-5-(trifluoromethyl)pyridine (0.18 g, 1.0 mmol, 1
equiv) and K2CO3 (0.28 g, 2.0 mmol, 2 equiv). Column
chromatography (20 → 60% EtOAc/pentane) afforded the product
(0.35 g, 0.92mmol, 92%). 1HNMR (300MHz, CDCl3): δ 8.44 (s, 1H),
8.03−7.76 (m, 1H), 7.26 (d, J = 7.7 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H),
7.01 (d, J = 8.6 Hz, 1H), 4.80−4.21 (m, 1H), 3.40 (q, J = 6.0 Hz, 2H),
2.82 (t, J = 6.9 Hz, 2H), 1.45 (s, 9H). 13C NMR (75 MHz, CDCl3): δ
165.95, 155.99, 151.80, 145.56, 136.77, 136.36, 130.28, 121.63, 111.48,




(65e). The title compound was prepared according to the general
procedure E using N-Boc-tyramine 64 (0.25 g, 1.05 mmol, 1.05 equiv),
2,4-dichloropyrimidine (0.15 g, 1 mmol, 1 equiv), and K2CO3 (0.21 g,
1.5 mmol, 1.5 equiv) in DMF (5 mL). The reaction was stirred for 19 h
at rt. Column chromatography (20 → 80% EtOAc/pentane) afforded
the product(0.22 g, 0.63 mmol, 63%).1H NMR (300 MHz, CDCl3): δ
8.42 (d, J = 5.7 Hz, 1H), 7.26 (d, J = 8.5 Hz, 2H), 7.13−7.03 (m, 2H),
6.78 (d, J = 5.7 Hz, 1H), 4.93−4.42 (m, 1H), 3.40 (q, J = 6.5 Hz, 2H),
2.83 (t, J = 7.0 Hz, 2H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3): δ
170.49, 160.66, 160.31, 155.91, 150.36, 137.23, 130.32, 121.30, 106.64,




α-Ketoacid formation: the α-ketoacid salt was prepared according to
the general procedure F using sodium pyruvate (0.44 g, 5.1 mmol, 1
equiv), 4-phenoxybenzaldehyde (1.0 g, 5.1 mmol, 1 equiv), and KOH
(0.42 g, 7.6 mmol, 1.5 equiv) in MeOH, affording potassium 4-(4-
phenoxyphenyl)-2-oxobut-3-enoate 62f (0.51 g, 1.9 mmol, 38%).
Amide coupling: the title compound was prepared according to the
general procedure C using potassium salt 62f (0.20 g, 0.93 mmol, 1
equiv), phenethylamine(0.26mL, 2.1mmol, 1.1 equiv), HCTU (0.87 g,
2.1 mmol, 1.1 equiv), and DiPEA (0.66 mL, 3.8 mmol, 2 equiv) in
DMF, affording the product (0.31 g, 0.82 mmol, 88%). 1H NMR (300
MHz, CDCl3): δ 7.93 (d, J = 15.9 Hz, 1H), 7.82−7.53 (m, 3H), 7.50−
7.16 (m, 9H), 7.16−6.91 (m, 4H), 3.76−3.48 (m, 2H), 2.91 (t, J = 6.8
Hz, 2H). 13C NMR (75 MHz, CDCl3): δ 185.23, 161.51, 160.85,
149.08, 147.45, 138.41, 131.18, 130.11, 129.07, 128.81, 126.78, 124.56,
120.11, 118.27, 117.19, 40.73, 35.59..
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